The idea in one sentence

Nuclear medicine is the only field in all of medicine that can image a disease at the molecular level and then treat that same molecular target — see it, then treat it, with the same biology. A ⁶⁸Ga-PSMA PET scan lights up every prostate-cancer deposit in the body; days later ¹⁷⁷Lu-PSMA delivers a therapeutic radiation dose to those exact deposits. The picture is the treatment plan. No other specialty works this way.

Why this is the future, not a niche

For decades nuclear medicine was a quiet corner of imaging. That era is over. The field is in the middle of a therapeutic transformation: radiopharmaceutical therapy is projected to grow from roughly $750 million (2022) to ~$5.5 billion by 2028, with 80+ new radioligand therapies in clinical development and pharmaceutical companies investing billions. Prostate cancer (PSMA) and neuroendocrine tumors (somatostatin receptor) are only the beginning — the same "one target, two isotopes" logic is being aimed at a growing list of cancers.

This is not incremental. The Lancet Oncology Commission estimated that meeting global demand for PSMA radioligand therapy alone would require more than half a million treatment doses per year — and "hundreds of new centers and more experts to deliver these therapies." The bottleneck is no longer the science. It is the number of trained physicians who can run these programs.

What makes it different from radiology

Diagnostic radiology reads anatomy — shape, size, density. Nuclear medicine reads biology — metabolism, receptor expression, perfusion, molecular targets — and then, uniquely, acts on it therapeutically. A radiologist characterizes a lesion; a nuclear medicine physician can characterize it and treat it, follow the dose, and adjust the next cycle. As oncology becomes precision oncology, the specialty that pairs a molecular diagnostic with a matched molecular therapy sits at the center of it.

If you are a medical student weighing radiology, this is the question worth sitting with: do you want to describe disease, or do you want to target and treat it at the molecular level — in a field that is expanding faster than it can be staffed?

The theranostic loop

The defining workflow is a loop: select patients by imaging the target (is the target there, and everywhere?), treat with the matched therapeutic isotope, quantify the delivered dose (dosimetry), and reassess to decide the next cycle. It is precision medicine made literal — the diagnostic and the therapeutic are the same molecule wearing a different isotope. Explore the Theranostics domain of this atlas to see the loop in practice, and the Landmark Trials chapter for the evidence that built it (VISION, NETTER-1/2, TheraP, ALSYMPCA).

The AI accelerant

If the therapy transformation is the field's engine, artificial intelligence is its accelerant — and nuclear medicine may be the imaging specialty AI changes most. The reason is structural: unlike anatomic radiology, nuclear medicine data is quantitative and numeric (SUV, counts, kinetics), and the theranostic loop is a self-labeling data engine — every patient imaged, treated, dosed, and reassessed generates exactly the paired imaging-and-outcome data that machine learning is starved for elsewhere. The immediate payoffs are already here: deep-learning denoising that lets scans run at a fraction of the dose or time, automated whole-body tumor-volume measurement in seconds, and — the biggest unlock — automated dosimetry that turns fixed-activity, one-size-fits-all therapy into personalized, dose-optimized treatment. Far from threatening the specialty, AI is what lets a too-small workforce meet exploding demand. For a student, that is the tell: nuclear medicine is where molecular biology, quantitative computing, and targeted therapy converge — see the AI & Machine Learning page for the full case.

The opportunity

Because demand for radiopharmaceutical therapy is outrunning the trained workforce, the career market is unusually strong — academic centers are increasingly hiring nuclear medicine physicians directly out of residency for faculty roles, a pattern that is expanding as programs race to open therapy services. The shortage spans the whole team — physicians, technologists, radiochemists, medical physicists, and radiopharmacists — but the physician who can lead a theranostics program is among the scarcest and most sought-after. Entering the field now means entering it at the moment it is being built out.

For the student deciding

You do not have to choose blindly. The training pathways page lays out exactly how to become a nuclear medicine physician — including routes through diagnostic radiology, so exploring nuclear medicine does not mean abandoning radiology. Spend time in a reading room during a theranostics clinic, watch a PSMA PET drive a treatment decision, and see whether the see-and-treat loop lights the same bulb it has lit for a generation of physician-scientists now shaping the field. The atlas exists to make that exploration easy: every tracer, target, therapy, and trial, in one place.

Related pages

• Theranostics Overview and the Therapy & Theranostics domain — the see-and-treat loop in clinical practice.
• The Therapy Transformation — the field-level shift and the workforce it demands.
• Becoming a Nuclear Medicine Physician — the training pathways, including via radiology.
• AI & Machine Learning in Nuclear Medicine — why AI may transform this field most, and the dosimetry unlock.
• Landmark Trials — VISION, NETTER-1/2, TheraP, ALSYMPCA, PSMAfore: the evidence base.

Quick Answer

Of all the imaging specialties, nuclear medicine may be the one AI is poised to change most — not just to read faster, but to remake the workflow. The reason is structural: nuclear medicine data is quantitative and numeric (SUV, counts, kinetics — signal a model can learn on, not just pictures), it is volumetric and multimodal (PET + CT/MR), it is paired with hard ground truth (pathology, response, survival), and — uniquely — it feeds a closed see→treat→quantify→reassess loop that generates exactly the labeled, outcome-linked data machine learning is hungry for. Deep learning is already contributing across that pipeline: denoising and deep-learning reconstruction (scans at lower dose or shorter time without losing quality), automated detection and segmentation (whole-body tumor volume in seconds, not an hour of manual contouring), automated dosimetry (the step that makes personalized radioligand-therapy dosing practical), and radiomic prognosis. The single biggest unlock is dosimetry: automating it converts fixed-activity, one-size-fits-all therapy into personalized, dose-optimized treatment at scale. The honest counterweight — kept front and center below — is that AI inherits real problems of generalization, bias, and explainability, so the realistic trajectory is profound augmentation with the physician still central, not replacement.

The revolution: why this field, specifically

Every imaging specialty is being touched by AI, but nuclear medicine has four features that make the impact deeper here than in anatomic radiology. First, its output is already a number — models train on quantitative signal, so the leap from "detect" to "measure" to "predict outcome" is short. Second, the theranostic loop is a self-labeling data engine: image the target, treat it, measure the delivered dose, watch the response — every patient generates paired imaging-and-outcome data, the scarce resource that limits medical AI elsewhere. Third, the field's rate-limiting manual step — voxel dosimetry — is precisely what AI automates well; removing that bottleneck is what turns personalized RPT from a research luxury into routine care, arguably the most consequential change coming to the specialty. Fourth, total-body/long-axial-FOV PET plus deep-learning denoising collapse dose and scan time so far that molecular imaging edges toward screening-scale accessibility. Layered on top of all this is a workforce shortage in an exploding therapy field (see the Therapy Transformation) — which makes an AI force multiplier not a threat to jobs but a necessity to meet demand.

Where it already helps

The nearest-term, most concrete applications:

Why NM is fertile ground

Three properties make molecular imaging a strong ML substrate. First, it is inherently quantitative — SUV, kinetic parameters, and counts are numbers, so models learn on signal, not just appearance. Second, studies are volumetric and multimodal (PET + CT/MR), giving rich input. Third, nuclear medicine sits close to ground-truth endpoints — biopsy, therapy response, survival — so models can be trained and validated against outcomes that matter. Total-body/long-axial-FOV PET compounds this by producing dynamic, whole-body, low-dose datasets ideal for data-hungry methods.

The honest limits

A tool is only as good as its validation in your setting. Key cautions: generalization — a model trained on one scanner/reconstruction/population may degrade on another (domain shift); bias — skewed training data produce skewed performance, potentially worsening care for under-represented groups; explainability — a black-box output is hard to trust or override at the point of care; and automation bias — the human tendency to defer to a confident algorithm. Responsible use means understanding a tool's training population, intended use, and failure modes, keeping a human in the loop, and treating regulatory clearance as a floor, not a guarantee of performance in your patients.

What it means for the field

For residents, fluency with these tools is becoming part of the craft — knowing when a denoised or AI-segmented output can be trusted, and when to revert to source data. For elite practitioners and program builders, AI is the enabler that makes personalized dosimetry and high-throughput quantitative reads practical — directly supporting the therapy transformation. For students weighing the field, it is part of why nuclear medicine is a frontier: a specialty where molecular signal, quantitative computing, and targeted therapy converge. The trajectory is augmentation — faster, lower-dose, more reproducible, more personalized — with the physician's judgment still central.

High-Yield Pearls

• Nuclear medicine may be the imaging field AI transforms most, because its data is quantitative-native and its theranostic loop is a self-labeling data engine.
• The biggest single unlock is automated dosimetry — turning fixed-activity therapy into personalized, dose-optimized treatment at scale.
• NM suits ML because it is quantitative, volumetric/multimodal, and outcome-linked.
• Nearest-term wins: denoising/DL-reconstruction (lower dose, faster), auto-segmentation (tumor volume), and automated dosimetry.
• MRAC and synthetic attenuation maps let PET/MRI quantify without CT.
• Real limits: generalization/domain shift, bias, explainability, automation bias — validate in your setting, keep a human in the loop.
• The realistic trajectory is augmentation, not replacement of interpretation.

Common Pitfalls

• Deploying a model outside its validated population/scanner and trusting the output.
• Automation bias — deferring to a confident algorithm over discrepant source data.
• Treating regulatory clearance as proof of performance in your specific patients.
• Ignoring training-data bias and its effect on under-represented groups.

Related Pages

• Context: Total-body & long-axial-FOV PET, Emerging & research PET tracers, SUV harmonization & EARL; vision: Why nuclear medicine — the future of imaging.

Self-Check

Key References

• Reviews of deep-learning reconstruction, denoising, segmentation, and dosimetry in PET/SPECT.
• Literature on AI generalization, bias, and explainability in medical imaging; regulatory frameworks for clinical AI tools.

Quick Answer

There is more than one road into nuclear medicine, which is exactly why a student interested in it should not feel forced to choose all at once. You can train in nuclear medicine directly (a dedicated residency), or reach it through diagnostic radiology (a nuclear-radiology fellowship or an integrated pathway), or come to it from another specialty. All roads share one rule: a year of general clinical training first, then a defined block of nuclear medicine training, then board certification (ABNM, or ABR via nuclear radiology). This page maps the routes; details and durations follow current board requirements, which evolve — always confirm against ABNM/ABR before planning.

The universal prerequisite

Every pathway requires one year of preparatory clinical training in direct patient care (a clinical internship/PGY-1) before entering nuclear medicine training. Nuclear medicine physicians manage patients — especially now, in the therapy era — so a foundation in clinical medicine is required across every route.

The main pathways to ABNM certification

The principal routes (durations are the nuclear-medicine training components; confirm current specifics with the board):

The practical takeaway for a student: you can keep the radiology door open. Several pathways embed nuclear medicine inside or after diagnostic-radiology training, so exploring nuclear medicine is not a bet against radiology — it is often a route through it toward the therapeutic, molecular side of the field.

ABNM vs ABR — two boards, one field

Nuclear medicine physicians are certified either by the American Board of Nuclear Medicine (ABNM) or, for those trained through radiology, by the American Board of Radiology (ABR) in nuclear radiology. Both credential a physician to interpret nuclear studies and to deliver radiopharmaceutical therapy under the appropriate authorized-user requirements. International graduates have separate alternate pathways (an ABR alternate pathway with a minimum block of nuclear medicine training, and an ABNM route for those already certified in nuclear medicine abroad).

Authorized-user status — the therapy credential

Delivering radiopharmaceutical therapy requires authorized-user (AU) status under radiation-regulatory rules (in the US, the NRC / Agreement States, governed by 10 CFR Part 35). Training pathways build the supervised hours and case experience that qualify a physician as an AU for the relevant categories of therapy — the credential that actually lets you write directives and treat patients with ¹³¹I, ¹⁷⁷Lu, ²²³Ra, ⁹⁰Y, and emerging agents. As the field turns therapeutic, AU eligibility is central to what a nuclear medicine physician does. See the atlas's Dosimetry, Safety & Regulatory domain for the written-directive and AU framework.

For programs and residents

This atlas is built to serve training directly: an evidence-graded reference across every tracer, protocol, disease, and therapy; a high-yield layer aligned to the board blueprint; a study mode over hundreds of self-check questions; and the Correlative CT and Therapy & Theranostics depth that modern practice demands. It is designed to sit alongside a residency curriculum as the always-current knowledge base — free, comprehensive, and physician-reviewed.

Related pages

• Why Nuclear Medicine — the case for the field, for students deciding.
• The Therapy Transformation — why the workforce demand is surging.
• Dosimetry, Safety & Regulatory — the written-directive and authorized-user framework.

Key References

• American Board of Nuclear Medicine (ABNM) — initial certification training requirements.
• American Board of Radiology (ABR) — nuclear radiology subspecialty pathways (including the 16-month pathway).

Quick Answer

Nuclear medicine may be the strongest job market in imaging right now, precisely because demand for radiopharmaceutical therapy is outrunning the trained workforce. Academic centers are hiring nuclear medicine physicians directly out of residency for faculty roles, hospitals and private groups are opening theranostics services, and industry is expanding fast. This page frames the market and points to the live, authoritative job boards where current openings actually are — kept current by the field's own organizations, so the listings never go stale.

Why the market is this strong

The therapy transformation created a structural workforce gap: radiopharmaceutical therapy is projected to grow from ~$750M (2022) to ~$5.5B by 2028, and the Lancet Oncology Commission estimated global demand would need hundreds of new centers and far more trained experts. That gap is the job market. The shortage spans physicians, technologists, radiochemists, medical physicists, and radiopharmacists — but the physician who can lead a theranostics program is among the scarcest and most sought-after. Entering now means entering a field being actively built out.

Where the live openings are

The definitive, continuously-updated source for nuclear-medicine roles is the SNMMI Career Center — searchable by function (academic, hospital, industry) and location:

Because these boards are maintained by the organizations themselves, they are always current — which is exactly why the atlas routes to them rather than mirroring listings that would go stale.

Types of roles

The field's roles have broadened with its transformation: academic faculty (clinical + research, increasingly offered straight from residency); hospital and private-practice nuclear medicine / theranostics; theranostics program leadership (building and running radiopharmaceutical-therapy services — a scarce, high-value skill); industry (medical affairs, clinical development, radiopharmacy/manufacturing); and research / physician-scientist tracks. Authorized-user status and program-building experience are the credentials that most differentiate candidates for the therapeutic roles.

How to land them

The practical path: complete a recognized training pathway (see Becoming a Nuclear Medicine Physician), build authorized-user eligibility for the therapies you want to deliver, and get hands-on theranostics experience — patient selection, dosimetry, and cycle management. Network through SNMMI and society meetings, where academic hiring often begins, and consider a fellowship (nuclear radiology, theranostics, or PET) to deepen a subspecialty. The scarcity is real enough that strong candidates have leverage.

A note on posting roles here

A native "post a role / browse openings" board on this site is a planned platform feature — it needs a backend for submissions, moderation, and automatic expiry so listings stay accurate. Until that exists, this hub deliberately routes to the live boards above rather than hosting static listings that would fill and go stale. When the platform is ready, the same structure hosts postings directly, and departments can list roles in a few fields.

Related pages

• Why Nuclear Medicine and The Therapy Transformation — the case and the market forces.
• Becoming a Nuclear Medicine Physician — training pathways and authorized-user status.

Key References

• SNMMI Career Center — the primary nuclear-medicine / molecular-imaging job board.
• Radiopharmaceutical-therapy workforce analyses (J Nucl Med 2025; Lancet Oncol 2024) — the demand/capacity gap driving hiring.

Quick Answer

Nuclear medicine is shifting from a primarily diagnostic specialty to a therapeutic one. Radiopharmaceutical therapy (RPT) — delivering targeted radiation to a molecular address — is growing explosively, and the rate-limiting step has become trained people, not molecules. Understanding this transformation is essential for anyone in the field: it is redefining what a nuclear medicine physician does, where the jobs are, and what training must cover.

The scale of the shift

The numbers describe a field being rebuilt in real time: RPT is projected to grow from roughly $750 million (2022) to ~$5.5 billion by 2028; 80+ radioligand therapies are in clinical development; and pharmaceutical companies have invested billions. The Lancet Oncology Commission estimated global demand exceeding half a million PSMA-therapy doses per year, requiring "hundreds of new centers and more experts." A 2022 estimate put eligible prostate and neuroendocrine patients at ~41,500, translating to ~150,000 treatment cycles annually — for two indications alone, before the pipeline arrives.

What is driving it

A handful of validated theranostic pairs proved the model, and the pipeline is widening it:

Two forces compound the growth: therapies are moving to earlier lines of treatment (each approval multiplies the eligible population), and new targets and alpha emitters are entering trials. The ²²⁵Ac supply that once throttled alpha therapy is now scaling up — removing a structural barrier to the next wave.

The workforce gap — the real bottleneck

Demand for RPT far exceeds current capacity to deliver it safely. The shortage spans the entire team — physicians, technologists, radiochemists, medical physicists, radiopharmacists, and allied staff — and there are not enough of any of them. The field's own literature is blunt that administering RPT without appropriate training and experience poses real risks to patients. This is the central challenge of the transformation: scaling delivery without compromising the safety and dosimetric rigor that make RPT work. In response, SNMMI has launched RPT Centers of Excellence and accreditation standards to spread capacity while holding quality.

What the field needs now

The transformation reframes the specialty's priorities: patient selection by imaging biomarkers (and recognizing discordant, target-negative disease); personalized dosimetry rather than fixed activities; longitudinal patient management across therapy cycles, including toxicity; radiation-safety and authorized-user competence at scale; and program-building skill — the ability to stand up a theranostics service. These are the competencies a modern nuclear medicine physician must own, and they are exactly what a training resource must now teach alongside classic diagnostic interpretation.

Why it matters for this atlas

A reference for this field can no longer be a diagnostic-imaging catalog with therapy as an afterthought. The atlas treats Therapy & Theranostics as a first-class domain — tracers, targets, dosimetry, response criteria, the landmark trials, and the safety/regulatory framework — precisely because that is where the field is going. The goal is that a physician anywhere in the world can use it to deliver modern, evidence-based radiopharmaceutical therapy safely, and that a trainee can build the therapeutic competencies the transformation demands.

Related pages

• Theranostics Overview and the Therapy & Theranostics domain — the clinical practice.
• Landmark Trials — the evidence base (VISION, NETTER-1/2, TheraP, ALSYMPCA, PSMAfore, ENZA-p).
• Why Nuclear Medicine and Becoming a Nuclear Medicine Physician — the case and the pathways.

Key References

• White paper on radiopharmaceutical therapy growth, workforce, and training needs, J Nucl Med 2025.
• Lancet Oncology Commission and reviews on theranostics workforce and training in the age of radiopharmaceutical therapy.

Start here

This is a guided tour, not a textbook chapter. Read these seven pages in order and you'll understand what nuclear medicine actually is, why it's different from radiology, and why it may be the most exciting specialty in imaging right now. Each link opens the page in the atlas — follow them top to bottom, then come back here for the next step.

The path

1 · Why Nuclear Medicine — The Future of Imaging — the one idea that defines the field: see a disease at the molecular level, then treat that same target. Start here for the "why."

2 · Molecular Imaging & the Theranostic Pair — how one molecule can carry either a diagnostic or a therapeutic isotope. This is the concept everything else builds on.

3 · FDG PET/CT in Oncology — the workhorse scan you'll see most: sugar metabolism as a map of cancer throughout the body.

4 · Theranostics — Overview — the see-and-treat loop in practice: image the target, treat it, measure the dose, reassess.

5 · ¹⁷⁷Lu-PSMA-617 — the flagship therapy: a PSMA PET lights up prostate cancer everywhere, then a matched drug delivers radiation to those exact deposits.

6 · AI & Machine Learning in Nuclear Medicine — why this quantitative, data-rich specialty may be the one AI transforms most.

7 · Becoming a Nuclear Medicine Physician — the training pathways, including routes through diagnostic radiology, if the see-and-treat loop lit the bulb.

Where to go next

If this sparked something, the natural next step is the Resident Core Curriculum for a structured deeper dive, or the Theranostics Deep-Dive if the therapy side is what grabbed you. Explore the Field & Future chapter for the careers and workforce picture — the field is hiring faster than it can train.

How to use this

This is a backbone, not a syllabus to finish in a week. Work through a domain at a time — ideally aligned with your rotations — reading the anchor pages, then branch into the rest of that chapter. Each domain below lists the highest-yield starting points; the full chapter (in the left navigation) holds the depth. Test yourself with Study mode as you go, and keep the High-yield toggle on for review passes.

Foundations — how the signal is made

Read first; everything else assumes it.

• Physics of Nuclear Medicine and Radiation Interactions with Matter — decay, emissions, LET.
• Radiation Detection & Instrumentation and PET & SPECT Performance & Reconstruction — how images are formed.
• Radiopharmaceuticals & Production — agents, generators, targets.

Cardiovascular

• Nuclear Cardiology — Overview → Myocardial Perfusion Imaging (SPECT) → Myocardial Viability (FDG PET) → Cardiac Amyloidosis.

Oncology

• FDG PET/CT in Oncology → FDG-PET Preparation & Physiologic Uptake → Lymphoma Staging — Lugano/Deauville. Then branch into the tumor-specific pages.

Endocrine & Neuroendocrine

• Differentiated Thyroid Cancer + Radioiodine — Thyroid → Parathyroid Imaging → Neuroendocrine Tumors.

Genitourinary

• Renal Scintigraphy + Tc-99m-MAG3 → PSMA PET agents.

Pulmonary

• V/Q Scan & Pulmonary Embolism — the classic, plus its decision logic in PE Imaging — Which Test When.

Musculoskeletal

• Bone Scintigraphy → Skeletal Metastases — Imaging.

Neurology

• Brain FDG & Dementia Imaging → I-123-Ioflupane (DaTscan) → Parkinsonism — FDG Metabolic Patterns.

Infection & Inflammation

• Infection & Inflammation Imaging → Labeled Leukocyte Scintigraphy → Osteomyelitis & the Diabetic Foot.

Gastrointestinal

• Cholescintigraphy (HIDA) → GI Bleeding & Meckel → Gastric Emptying.

Therapy & theranostics

• Theranostics — Overview → ¹⁷⁷Lu-PSMA-617 + ¹⁷⁷Lu-DOTATATE → Differentiated Thyroid Cancer — I-131 Therapy → Radionuclide Therapy — Eligibility & Toxicity Monitoring.

Safety, quality & call

Non-negotiable for practice and the exam.

• Radiation Safety & Patient Release and Pregnancy & Lactation in Nuclear Medicine.
• Protocoling & Appropriate Use and On-Call & STAT Nuclear Medicine — the practical craft.

When you're consolidating

Switch to the Board Blitz — High-Yield Sprint for the patterns, thresholds, and trials, and drill everything in Study mode.

How to run the sprint

In the final weeks, breadth beats depth. Turn on the High-yield toggle (top of the navigation) so every page collapses to its key points, work through the pattern and framework pages below, then spend most of your time in Study mode — draw sets, self-score, and re-drill your misses. Study mode now labels each question with its topic, and can filter by domain or drill only your missed questions.

Pattern recognition — the "what is this?" pages

The exam loves a pattern. Know these cold.

• Superscan · Photopenic (Cold) Lesions · Flare Phenomenon
• Physiologic FDG Uptake & Benign Mimics · Attenuation & Misregistration Artifacts
• Discordant PSMA / FDG Disease · Incidental Findings on FDG-PET/CT

Which test when — modality/tracer selection

High-yield decision logic, tested constantly.

• PE Imaging — Which Test When · Bone Metastasis Imaging · Dementia & Movement-Disorder Imaging
• Neuroendocrine Tumor Imaging · Parathyroid Imaging · Prostate Cancer Imaging · Cardiac Viability Imaging · Infection Imaging

Reporting & response frameworks

Scores and criteria that show up as stems.

• Lymphoma Staging — Lugano/Deauville · Oncology Response — RECIST & PERCIST · PSMA-PET Reporting — PROMISE & PSMA-RADS

Numbers & preparation

The values you must have memorized.

• Quantitative Thresholds & Decision Cutoffs · Patient Preparation & Study Confounders
• Effective Dose Reference · Radiation Safety & Patient Release

Landmark trials

Know the design, result, and why it changed practice.

• VISION · TheraP · NETTER-1 / NETTER-2 · ALSYMPCA · proPSMA · PIOPED — full set in the Landmark Trials chapter.

Then: drill

Reading is recognition; Study mode is recall. Draw a mixed set across all domains, self-score honestly, and use "Drill missed" until the misses are gone. Re-take the day before as a confidence pass.

Who this is for

This track is for the resident or attending who wants to practice radioligand therapy, not just know it exists. It runs from the underlying concept through the two established theranostic pairs, into dosimetry, toxicity, and the operational reality of running a program — and ends at the pipeline that is redefining the field.

The concept

• The Therapy Transformation — the field-level shift and the workforce it demands.
• Molecular Imaging & the Theranostic Pair → Theranostics — Overview — the see-and-treat loop.

The two established pairs

Neuroendocrine (SSTR): ⁶⁸Ga-DOTATATE PET to select → ¹⁷⁷Lu-DOTATATE (PRRT) to treat.

Prostate (PSMA): PSMA PET agents to select → ¹⁷⁷Lu-PSMA-617 to treat; refine selection with Discordant PSMA / FDG Disease.

Dose, response & toxicity

• Personalized vs Fixed-Activity Dosimetry and Dosimetry in Theranostics — why absorbed dose, not activity, is the right prescription.
• Theranostics Response Criteria — how to call response.
• Radionuclide Therapy — Eligibility & Toxicity Monitoring — organs at risk and mitigation.

Running it in the real world

• Building & Running a Theranostics Program — facility, license, team, workflow, and the perishable-dose economics.
• Sequencing, Retreatment & Combinations in RPT — where RPT sits among the lines.

The frontier

• Targeted Alpha Therapy (Ac-225, Pb-212) and Emerging Therapeutic Targets & Isotopes — FAP, GRPR, CXCR4, and the alpha pipeline.
• AI & Machine Learning in Nuclear Medicine — why automated dosimetry is the change that makes personalized therapy routine.

The evidence base

Anchor every claim above to the trials that built the field: VISION · PSMAfore · TheraP · ENZA-p · NETTER-1 / NETTER-2 · ALSYMPCA — the full set is in the Landmark Trials chapter.

Quick Answer

Radionuclides decay by emitting particles or photons whose properties determine whether an isotope is suited to imaging or therapy. Gamma and positron emitters (Tc-99m, F-18, Ga-68) are for imaging because their photons escape the body to a detector. Particle emitters — beta (β⁻) (Lu-177, Y-90, I-131) and alpha (α) (Ra-223, Ac-225) — deposit energy locally over millimeters or micrometers, which makes them therapeutic. Linear energy transfer (LET) and half-life are the two properties that most shape efficacy and radiation protection.

Why Physics Matters Clinically

A therapy-capable nuclear-medicine physician explains why a given isotope is chosen and how its dose is delivered. Decay mode sets the imaging/therapy role; LET sets biological potency; half-life sets logistics, retained activity, and patient-release rules. These physical properties are the foundation of every theranostic decision.

Radiation Quantities (Orientation)

• Activity — becquerel (Bq) / curie (Ci): decays per unit time.
• Absorbed dose — gray (Gy): energy per unit mass.
• Equivalent dose — sievert (Sv): absorbed dose weighted for radiation type (α weighted heavily).
• Effective dose — Sv: equivalent dose weighted by tissue radiosensitivity (compares whole-body stochastic risk).

Decay Modes

Particle Range & LET

• Beta particles travel millimeters (low-to-moderate LET), giving a useful crossfire effect across cell clusters — good for bulkier/heterogeneous disease. Lu-177 conveniently also emits an imageable γ (post-therapy SPECT/dosimetry).
• Alpha particles travel only a few cell diameters (micrometers) but carry very high LET, producing dense, clustered DNA double-strand breaks that are largely irreparable and relatively independent of oxygenation and dose rate. This makes alphas potent against micrometastatic/radioresistant disease, at the cost of harder dosimetry and daughter-nuclide concerns (e.g. Ac-225's recoiling progeny).

Half-Life & Decay

Physical half-life governs how quickly activity decays: A = A₀·e^(−0.693·t/t½). It sets pre-calibration/decay corrections and achievable protocols (Rb-82's 76-second half-life forces on-generator, pharmacologic-stress-only workflows). With biological clearance it yields the effective half-life that drives radiation dose and patient-release timing.

Effective Half-Life — the Number That Governs Dose

Radiation dose and patient-release timing depend on the effective half-life, not the physical one alone:

1/t½(eff) = 1/t½(physical) + 1/t½(biological)

A tracer that is physically long-lived but rapidly excreted delivers less dose than its physical half-life suggests, and vice versa.

Generator Equilibria (Preview)

Generators exploit parent→daughter decay: transient equilibrium (Mo-99 → Tc-99m; parent half-life somewhat longer than daughter) and secular equilibrium (very long-lived parent, e.g. Sr-82 → Rb-82 / Ge-68 → Ga-68). See the radiopharmaceuticals page for the practical elution logic.

Positron Range & PET Resolution

A positron travels a short distance before annihilation — positron range blurs the reconstructed location, larger for higher-energy emitters (Rb-82, Ga-68) than for F-18 (one reason F-18 agents look sharper). The two 511-keV photons are also not emitted at exactly 180° (a small angular deviation), adding a further, scanner-diameter-dependent resolution limit.

Choosing an Isotope — the Summary Logic

Imaging needs escaping photons (γ for SPECT; positrons → 511 keV for PET); therapy needs locally deposited particle energy (β for mm-range crossfire, α for µm-range high-LET kill). Half-life sets logistics (generator vs cyclotron vs distribution) and, with biological clearance, dose to the patient and others. A single element can serve both ends of a theranostic pair when chemistry allows (Ga-68 image / Lu-177 treat on the same DOTA-conjugated ligand).

Board Pearls

Imaging isotopes must emit escaping photons; therapy isotopes must deposit particle energy locally — the same element can do both across a theranostic pair (e.g. Ga-68/Lu-177 on the same ligand). Radiation dose and patient-release timing depend on effective half-life, not physical half-life alone.

Alpha vs beta is the crux of the modern therapy conversation: alphas are high-LET, micrometer-range, oxygen/dose-rate-independent (potent against micrometastases, harder dosimetry, daughter-nuclide concerns); betas are mm-range with crossfire for bulkier disease.

Positron range blurs PET localization — larger for high-energy emitters (Rb-82, Ga-68) than F-18 — and the small non-180° annihilation-photon deviation adds a scanner-size-dependent limit. These physics set the resolution ceiling before any reconstruction choice. Effective half-life combines physical decay with biological clearance to determine actual dose.

Related Pages

• Calculators: decay and effective dose tools.
• Related: Radiopharmaceuticals & production, radiation detection & instrumentation, radiation biology & protection.

Figure / Diagram Suggestions

• A decay-mode chart mapping emission → imaging/therapy role.
• An α vs β range/LET comparison (µm high-LET vs mm crossfire).
• An effective half-life schematic (physical ⊕ biological clearance).

Self-Check (Board-Style)

Quick Answer

Photons interact with matter mainly by the photoelectric effect and Compton scatter (with pair production only above 1.022 MeV). The photoelectric effect — full absorption, probability ∝ Z³/E³ — dominates at low energy and in high-Z materials (bone, iodine contrast, lead shielding) and is the basis of attenuation contrast and gamma shielding. Compton scatter — partial energy transfer to an outer electron — dominates in soft tissue at the diagnostic/PET energies (~140–511 keV) and is the source of scattered photons that degrade images (mitigated by energy windowing and scatter correction). Overall photon attenuation is exponential (μ, half-value layer), the physics behind attenuation correction.

The Interactions

Photoelectric Effect

An incident photon is completely absorbed by an inner-shell electron, which is ejected (photoelectron), followed by characteristic X-rays / Auger electrons. Probability rises steeply with atomic number (∝ Z³) and falls with energy (∝ 1/E³) — so it dominates at low photon energies and in high-Z materials. Consequences: bone/contrast/lead attenuate strongly (imaging contrast and shielding), and there is no scattered photon to degrade the image.

Compton Scatter

The photon interacts with a loosely bound outer-shell electron, transferring part of its energy and scattering in a new direction (the recoil electron carries the rest). It is nearly independent of Z and depends on electron density, so it dominates in soft tissue across ~30 keV–~20 MeV — i.e., at all common NM energies (140 and 511 keV). Consequences: scattered photons are the main source of image degradation (loss of contrast, mispositioned counts) — countered by energy-window (photopeak) discrimination and scatter correction.

Pair Production

Above the 1.022 MeV threshold, a photon near a nucleus converts to an electron–positron pair; the positron later annihilates into two 511-keV photons. It is not relevant at diagnostic/PET imaging energies but matters for high-energy (therapy/linac) contexts.

Coherent (Rayleigh) Scatter

Elastic scatter with no energy loss and small-angle deflection — a minor contributor at NM energies.

Attenuation

A photon beam is attenuated exponentially: I = I₀ · e^(−μx), where μ is the linear attenuation coefficient (sum of the interaction probabilities). Useful quantities:

• Half-Value Layer (HVL): thickness reducing intensity by half; HVL = 0.693/μ.
• Mass attenuation coefficient (μ/ρ): normalizes for density, tabulated by material/energy.
• Attenuation is energy- and material-dependent — the basis of CT-based attenuation maps used to correct SPECT/PET.

Why It Matters in Nuclear Medicine

• Photopeak windowing accepts primary photons and rejects Compton-scattered (lower-energy) photons.
• Scatter correction models and subtracts the Compton-scatter background (SPECT and PET).
• Attenuation correction uses the material-dependent μ map (CT) — patient tissue attenuates 140/511-keV photons, and uncorrected attenuation causes artifacts (e.g., inferior-wall cardiac defects).
• Shielding exploits the photoelectric effect in high-Z lead for gamma emitters (recall beta emitters need low-Z first, then lead to limit bremsstrahlung).
• Collimation and detector stopping power (high-Z NaI/BGO/LSO) likewise rely on photoelectric absorption of the photopeak.

Common Pitfalls

• Assuming photoelectric dominates in tissue at NM energies — Compton does (140/511 keV in soft tissue).
• Forgetting pair production requires >1.022 MeV (irrelevant to diagnostic imaging).
• Ignoring uncorrected attenuation as an artifact source (e.g., cardiac inferior wall).
• Shielding beta sources with lead alone (bremsstrahlung) — a photoelectric-shielding rule that does not transfer to particles.

Board Pearls

Photons interact chiefly by the photoelectric effect (full absorption; probability ∝ Z³/E³; dominates at low energy / high-Z — bone, contrast, lead shielding; no scatter) and Compton scatter (partial energy transfer to an outer electron; ∝ electron density, Z-independent; dominates in soft tissue at 140/511 keV; the source of image-degrading scatter). Pair production needs >1.022 MeV and is irrelevant to diagnostic imaging.

Overall attenuation is exponential (I = I₀e^(−μx)); HVL = 0.693/μ. Compton scatter is countered by photopeak energy windowing and scatter correction; tissue attenuation is corrected by the CT-based μ map (uncorrected attenuation → artifacts such as the inferior-wall cardiac defect).

Photoelectric absorption in high-Z materials underlies gamma shielding (lead), collimator septa, and detector stopping power (NaI/BGO/LSO). It is energy-dependent — the same lead is far more effective against low-energy photons. For beta emitters, shield low-Z first then lead (bremsstrahlung) — the photoelectric shielding logic applies to photons, not particles.

Related Pages

• Physics: Physics of nuclear medicine, radiation biology & protection; instrumentation: radiation detection & instrumentation, PET/SPECT performance & reconstruction (scatter/attenuation correction).

Figure / Diagram Suggestions

• An interaction-vs-energy dominance chart (photoelectric / Compton / pair production by energy and Z).
• A photoelectric vs Compton event cartoon (full absorption vs scatter).
• An exponential attenuation / HVL curve.

Self-Check

Quick Answer

Radioactive decay is a Poisson process, so the standard deviation of a count N is √N and the fractional (percent) error is 1/√N. Achieving 1% precision requires 10,000 counts; 5% requires 400. Errors propagate — variances add for sums/differences, fractional variances add for products/quotients — which governs net-count (signal-minus-background) uncertainty. The chi-square test checks system reproducibility, and ROC/AUC analysis compares diagnostic performance independent of any single threshold.

Poisson Statistics — the Foundation

For a Poisson-distributed count N:

• Standard deviation: σ = √N
• Fractional (relative) error: σ/N = 1/√N; percent error = 100/√N
• 95% confidence ≈ N ± 1.96√N

The practical corollary: precision improves only as the square root of counts — a 10× improvement in precision needs 100× the counts (or time). This is why low-count studies (delayed images, small ROIs, short frames) are inherently noisier.

Error Propagation

• Sum or difference (A ± B): add variances → σ = √(σ²_A + σ²_B) = √(A + B) for counts.
• Product or quotient (A×B or A/B): add fractional variances (relative errors in quadrature) → (σ/R)² = (σ_A/A)² + (σ_B/B)².
• Multiply by a constant k: σ scales by k; fractional error unchanged.

Worked: Net Counts (Signal − Background)

Net = Gross − Background. Because both are counts, the variance of the net = Gross + Background (not Gross − Background):

• Gross = 1,000; Background = 200 → Net = 800
• σ_net = √(1000 + 200) = √1200 ≈ 34.6
• Fractional error = 34.6/800 = 4.3%

Note the net count (800) has more relative uncertainty than the gross count alone — background subtraction always increases relative error, the reason high background (or low target-to-background) degrades quantitation.

The Chi-Square Test (Reproducibility)

Repeated measurements of a constant source should vary only by Poisson statistics. χ² = Σ(Nᵢ − N̄)² / N̄ over n measurements; the value is compared to tabulated ranges for (n−1) degrees of freedom. An out-of-range χ² indicates the system is varying more (instability) or less (something suppressing normal variation) than Poisson statistics allow — a QC red flag for camera/counter reproducibility.

Dead Time & Count-Rate Losses

At high count rates, detectors miss events during the processing ("dead") time:

• Nonparalyzable model: measured rate saturates toward a maximum.
• Paralyzable model: measured rate rises, peaks, then falls at very high rates (each event extends the dead period) — dangerous because a very high true rate can read as a low one.
• Relevant to first-pass, Rb-82 cardiac, and high-activity therapy imaging; corrected by system dead-time models.

Minimum Detectable Activity

The smallest signal distinguishable from background depends on background counts and counting time (e.g. Currie's L_D). Practically: lower background and longer counting lower the detection limit — the basis for wipe-test and contamination-survey sensitivity.

Diagnostic Performance — Beyond a Single Threshold

PPV/NPV depend on prevalence (Bayes): the same test performs differently in a screening vs a high-prevalence population — a normal MPI's high NPV (the "warranty period") reflects low pretest risk as much as test performance.

ROC / AUC — Threshold-Independent Comparison

A receiver-operating-characteristic (ROC) curve plots sensitivity (TPF) vs 1 − specificity (FPF) across all thresholds. The area under the curve (AUC) summarizes discrimination:

• AUC 1.0 = perfect; 0.5 = chance (diagonal).
• ROC compares observers, systems, or tracers independent of any single cutoff — the standard method for imaging-performance studies (and for justifying a chosen operating threshold).

Board-Level Synthesis

Decay is Poisson: σ = √N, percent error = 1/√N — so 10,000 counts = 1%, 400 = 5%, and precision improves only as the square root of counts (10× precision needs 100× counts). Net-count variance = Gross + Background, so background subtraction always raises relative error.

Error propagation: add variances for sums/differences, add fractional variances for products/quotients. The chi-square test flags a system varying more (or less) than Poisson statistics allow — a reproducibility QC check.

PPV/NPV are prevalence-dependent (Bayes) — the same sensitivity/specificity gives different predictive values across populations. ROC/AUC compares diagnostic performance independent of threshold (AUC 1.0 perfect, 0.5 chance), the correct way to compare tracers/observers/systems. At high count rates, paralyzable dead time can make a very high true rate read falsely low.

Related Pages

• Physics: Physics of nuclear medicine, radiation detection & instrumentation (dead time, QC).
• Reference: Quality control procedures (chi-square/constancy in practice).

Figure / Diagram Suggestions

• A √N precision curve (counts vs % error) with the 400/10,000 landmarks.
• A net-count error worked schematic (gross, background, propagated σ).
• An ROC curve with AUC and the sensitivity/specificity trade-off.

Self-Check

Quick Answer

Radiation effects are either stochastic (probability of harm — chiefly cancer — rises with dose, no threshold under the linear-no-threshold model; severity is fixed) or deterministic / tissue reactions (occur above a threshold, with severity rising with dose — skin injury, marrow suppression, cataract). Protection follows ALARA (as low as reasonably achievable) using time, distance, and shielding, within regulatory dose limits. Diagnostic nuclear medicine operates in the stochastic-risk range; therapy dosimetry manages deterministic organ limits (marrow, kidney, lung, salivary).

Key Quantities

Effective dose lets disparate procedures be compared on one stochastic-risk scale (e.g., an FDG-PET/CT vs a bone scan).

Stochastic vs Deterministic

Dose Limits (Representative, ICRP-based)

• Occupational: ~20 mSv/year effective dose (averaged over defined periods); separate limits for lens of the eye (~20 mSv/yr under ICRP) and extremities/skin (~500 mSv/yr).
• Public: ~1 mSv/year effective dose.
• Declared pregnancy: additional constraint to protect the embryo/fetus (e.g., ~1 mSv over the declared term under some frameworks).

(Exact limits are set by the applicable regulator — NRC/Agreement States or national body — verify locally; US NRC occupational limit is 50 mSv/yr, differing from ICRP's 20.)

ALARA in Practice

• Time: minimize time near sources.
• Distance: the inverse-square law — doubling distance quarters exposure — is the most powerful lever.
• Shielding: lead for gamma; for beta emitters, low-Z material first (acrylic/plastic) then lead, because lead alone generates penetrating bremsstrahlung X-rays.
• Plus contamination control, dosimetry badges, and workflow design.

Worked Point

A tech stands 30 cm from a source reading 4 mR/hr. Stepping back to 90 cm (3×) drops exposure by 3² = 9×, to ~0.44 mR/hr — distance beats most shielding for quick gains.

Reporting / Practice Notes

• Frame diagnostic risk in effective dose terms; frame therapy limits in absorbed dose to organs at risk.
• Apply ALARA (time/distance/shielding) and document occupational dose (badges).
• Match shielding to emission (low-Z-then-lead for beta).

Common Pitfalls

• Applying deterministic-threshold thinking to stochastic (no-threshold) cancer risk — or vice versa.
• Shielding high-energy beta sources with lead alone (generates bremsstrahlung).
• Confusing NRC (50 mSv/yr) with ICRP (20 mSv/yr) occupational limits.
• Neglecting the inverse-square law as the cheapest dose-reduction tool.

Board Pearls

Radiation effects split into stochastic (probability of cancer/heritable harm rises with dose, no threshold under LNT, severity fixed) and deterministic/tissue reactions (occur above a threshold, severity rises with dose — skin injury, marrow suppression, cataract). Diagnostic nuclear medicine lives in the stochastic range managed by ALARA (time, distance, shielding); therapy dosimetry manages deterministic organ limits (marrow, kidney, lung, salivary).

Effective dose (Sv) weights equivalent dose by tissue radiosensitivity, letting disparate procedures compare on one stochastic-risk scale. The inverse-square law is the most powerful practical lever — tripling distance cuts exposure ~9×.

Keep the dose chain straight: absorbed dose (Gy) → equivalent dose (Sv) (radiation weighting; α = 20) → effective dose (Sv) (tissue weighting). Representative limits: ICRP ~20 mSv/yr occupational, ~1 mSv/yr public — but the US NRC uses 50 mSv/yr occupational, so verify the applicable regulator. For beta emitters, shield with low-Z first (acrylic) then lead; lead alone generates penetrating bremsstrahlung and worsens the exposure it was meant to stop.

Related Pages

• Physics: PET/SPECT performance, radiation safety & patient release; safety niches: contamination/accident management.

Figure / Diagram Suggestions

• A stochastic vs deterministic dose–response pair (probability vs severity curves).
• An inverse-square exposure-vs-distance plot.
• A beta-shielding schematic (acrylic-then-lead vs bremsstrahlung from lead alone).

Self-Check

Quick Answer

Nuclear medicine detects the photons emitted by radiopharmaceuticals. The gamma camera (scintillation crystal + photomultipliers + a collimator that defines direction) produces planar and SPECT images from single gammas. PET instead detects the two 511-keV photons from positron annihilation in coincidence, needing no physical collimator — giving higher sensitivity and resolution. Dose calibrators and well counters quantify activity, and a defined quality-control program keeps all of it accurate.

The Gamma Camera (SPECT)

A sodium-iodide (NaI(Tl)) crystal (or CZT semiconductor) converts gamma photons to light/charge; photomultiplier tubes (or direct readout) localize and quantify each event via Anger logic. Because gammas travel in all directions, a collimator (lead septa) accepts only photons traveling in a defined direction — the fundamental resolution/sensitivity trade-off in SPECT:

• Low-energy high-resolution vs high-sensitivity collimators trade counts for sharpness.
• Higher-energy isotopes (I-131) need medium/high-energy collimators.
• CZT (solid-state) cameras improve energy resolution and enable compact, high-sensitivity cardiac systems.

PET Detection

Positron annihilation yields two 511-keV photons ~180° apart. Detecting both within a coincidence window defines the line of response — electronic collimation — which is why PET is far more sensitive than SPECT. Detector crystals (LSO/LYSO, historically BGO) are chosen for high stopping power and fast timing. Time-of-flight (TOF) uses the tiny arrival-time difference to localize the annihilation along the line, improving signal-to-noise (especially in larger patients).

Detector Materials at a Glance

Non-Imaging Instruments

• Dose calibrator: an ionization chamber measuring administered activity before every dose — the daily accuracy check behind therapy and diagnostics.
• Well counter: high-sensitivity counting of small samples (blood dosimetry, wipe tests).
• Survey / GM meters: contamination and exposure monitoring for radiation safety.

Quality Control (Representative)

The Collimator Is the SPECT Bottleneck

In SPECT, the collimator — not the crystal — sets the resolution/sensitivity trade-off, because it discards all photons except those traveling in a defined direction. PET needs no physical collimator (coincidence = electronic collimation), which is why PET has fundamentally higher sensitivity and resolution than SPECT.

Matching the Collimator to the Isotope

Use a collimator energy rating matched to the isotope: low-energy for Tc-99m (140 keV) and Tl-201; medium/high-energy for I-131 (364 keV) and Ga-67. A low-energy collimator with a high-energy isotope produces septal-penetration artifacts (star/streak patterns) that mimic or obscure disease.

Reporting / QC Impact

• Daily uniformity and energy-peak checks catch non-uniformities that project as ring/patchy SPECT artifacts.
• Periodic center-of-rotation, resolution, and linearity checks preserve reconstruction fidelity.
• PET/CT daily normalization/blank and cross-calibration keep SUV quantitative.
• The dose calibrator stands behind every administered activity — its daily constancy check is non-negotiable; geometry/linearity errors propagate directly into patient dose.

Common Pitfalls

• Non-uniformity / center-of-rotation errors producing SPECT ring/artifact patterns.
• Low-energy collimator with a high-energy isotope → septal-penetration artifacts.
• CT-based attenuation misregistration on hybrid systems from patient motion/respiration.
• Uncorrected dose-calibrator errors propagating into administered activity.

Board Pearls

The collimator is the resolution-limiting element of SPECT (it discards most photons); PET's coincidence detection removes it, giving PET fundamentally higher sensitivity and resolution. TOF further improves PET signal-to-noise.

Match collimator energy to the isotope — a low-energy collimator with I-131 (364 keV) causes septal-penetration (star) artifacts. The dose calibrator is the instrument behind every administered activity; its daily constancy check is non-negotiable.

Daily gamma-camera uniformity/energy-peak checks catch non-uniformities that become ring/patchy SPECT artifacts; center-of-rotation, resolution, and linearity checks preserve reconstruction fidelity. On PET/CT, daily normalization/blank and cross-calibration keep SUV quantitative, and CT–emission misregistration (motion/respiration) is the classic hybrid artifact.

Related Pages

• Related: Physics of nuclear medicine, SPECT/PET & hybrid imaging, radiopharmaceuticals & production.
• Pitfalls: Pearls, pitfalls & normal variants (free-pertechnetate, collimator artifacts).

Figure / Diagram Suggestions

• A gamma-camera cross-section (collimator → crystal → PMTs → Anger logic).
• SPECT collimator vs PET coincidence (physical vs electronic collimation).
• A QC artifact plate (non-uniformity ring, septal-penetration star, misregistration defect).

Self-Check (Board-Style)

Quick Answer

A defined quality-control program keeps imaging quantitative and detects failures before they mimic disease. The essentials: gamma camera — daily uniformity and energy peak, periodic spatial resolution/linearity (bar phantom) and SPECT center-of-rotation (COR); PET/CT — daily normalization/blank and cross-calibration; dose calibrator — daily constancy, periodic linearity, accuracy, geometry; generator — Mo-99 breakthrough (≤ 0.15 µCi/mCi) and aluminum (≤ 10 µg/mL). Each test has a cadence and an acceptance criterion; failing one has a characteristic artifact.

Gamma Camera (SPECT) QC

Extrinsic floods include the collimator (test the clinical system); intrinsic floods are without the collimator (test the detector). A non-uniformity projects as a ring artifact at the corresponding radius on SPECT — the single most important reason daily uniformity is mandatory.

PET/CT QC

A miscalibrated cross-calibration (scanner, dose calibrator, and clock must agree) silently biases SUV — a quantitation error, not a visual one.

Dose Calibrator QC

The instrument behind every administered activity — its QC is non-negotiable:

Well Counter & Survey Instruments

• Well counter: daily constancy and energy calibration; efficiency for quantitative counting (blood dosimetry, wipe tests).
• Survey / GM meters: annual calibration, daily battery/constancy check; used for contamination and exposure surveys and package/area monitoring.

Generator & Radiopharmaceutical QC

Failure → Artifact Map

Board-Level Synthesis

The daily anchors are gamma-camera uniformity + energy peak, PET normalization/blank, and dose-calibrator constancy. The periodic anchors are bar-phantom resolution/linearity and SPECT COR (weekly–monthly), and dose-calibrator linearity (quarterly)/accuracy (annual)/geometry (install).

A non-uniformity projects as a ring artifact at the corresponding SPECT radius, and a COR error causes doughnut/tuning-fork blurring — the two failures most likely to mimic or obscure disease, and the reason their QC is frequent.

Two limits anchor generator radionuclidic/chemical purity: Mo-99 breakthrough ≤ 0.15 µCi/mCi and aluminum ≤ 10 µg/mL. The dose calibrator underlies every administered activity — daily constancy, quarterly linearity, annual accuracy, and geometry at install — and PET cross-calibration (scanner ↔ dose calibrator ↔ clock) keeps SUV trustworthy, a quantitation error that is invisible on the image.

Related Pages

• Physics: Radiation detection & instrumentation, counting statistics & ROC (chi-square/constancy), radiopharmaceuticals & production (generator QC).
• Pitfalls: Pearls, pitfalls & normal variants (artifacts).

Figure / Diagram Suggestions

• A QC cadence calendar (daily/weekly/quarterly/annual by instrument).
• A failure → artifact plate (ring, doughnut, septal-penetration star).
• A dose-calibrator four-test schematic (constancy/accuracy/linearity/geometry).

Self-Check

Quick Answer

SPECT resolution is limited chiefly by the collimator (resolution degrades with source-to-collimator distance) and combines with intrinsic detector resolution in quadrature. PET needs no physical collimator (coincidence detection) but is bounded by positron range, photon non-collinearity, and detector element size; its signal is the true coincidences against scatter and randoms, summarized by the noise-equivalent count rate (NECR). Iterative reconstruction (OSEM) with PSF and time-of-flight (TOF) modeling, plus attenuation/scatter/partial-volume corrections, turn raw data into quantitative images.

SPECT — Resolution & Sensitivity

System resolution combines detector (intrinsic) and collimator (geometric) terms in quadrature:

R_system = √(R_intrinsic² + R_collimator²)

• The collimator dominates and degrades with distance from the collimator face — so keep the detector close to the patient.
• Resolution–sensitivity trade-off: high-resolution collimators accept fewer photons (lower sensitivity); high-sensitivity collimators blur. A converging (fan/cone) collimator or CZT/dedicated cardiac geometry can improve one without fully sacrificing the other.
• Pinhole collimation magnifies for high-resolution small-organ imaging (thyroid, parathyroid, small-animal).

PET — Intrinsic Resolution Limits

Even with electronic collimation, PET resolution is bounded by physics:

These set a practical whole-body PET resolution around a few millimeters — the floor beneath which no reconstruction can recover true detail.

PET — Coincidences: True, Scatter, Random

• True coincidence: both photons from one annihilation, unscattered — the signal.
• Scatter coincidence: one/both photons Compton-scattered — mispositioned; removed by scatter correction.
• Random (accidental) coincidence: two photons from different annihilations within the timing window — increase with the square of activity; corrected by the delayed-window technique.
• Noise-equivalent count rate (NECR) = T²/(T + S + R) — the effective signal-to-noise metric that peaks then falls as activity rises (randoms/dead-time dominate at high activity), guiding optimal injected activity.

Time-of-Flight (TOF)

Fast detectors measure the arrival-time difference of the two photons and localize the annihilation along the line of response, narrowing the probable position. TOF improves signal-to-noise (effective sensitivity gain that scales with patient size) — most valuable in larger patients.

Image Reconstruction

• Filtered back-projection (FBP): fast, linear, but streak-artifact-prone and noisy — largely historical for clinical use.
• Iterative (OSEM): models the acquisition (system matrix) and iterates toward the image; subsets × iterations trade convergence against noise. Incorporates:
• PSF / resolution recovery — models spatially varying blur (sharper images; can introduce edge "Gibbs" overshoot and change SUV).
• TOF (PET) — improves SNR/convergence.
• Reconstruction settings change SUV, so quantitative comparison requires matched reconstruction (or an EARL-harmonized reconstruction).

Quantitative Corrections

The Partial-Volume Effect & Recovery Coefficient

Structures smaller than ~2–3× the system resolution (FWHM) have their activity underestimated (spill-out) and background overestimated (spill-in). The recovery coefficient (measured/true activity) falls below 1 as size decreases — the physical reason a small avid nodule can show a falsely low SUV, and a caution in serial small-lesion quantitation.

NEMA Performance Standards

NEMA NU-2 (PET) and NU-1 (SPECT) standardize measurement of spatial resolution, sensitivity, scatter fraction, NECR, count-rate performance, and image quality, enabling scanner comparison and acceptance testing.

Board-Level Synthesis

SPECT resolution is collimator-limited and degrades with distance — combine intrinsic and collimator terms in quadrature and keep the detector close. PET floor is set by positron range, non-collinearity (~0.5°, worse at larger ring diameter), and detector element size — no reconstruction recovers detail below it.

PET signal is true coincidences against scatter and randoms (randoms ∝ activity²); NECR = T²/(T+S+R) peaks then falls with activity, guiding optimal dose. TOF localizes the annihilation along the line of response, improving SNR most in larger patients.

Iterative reconstruction (OSEM) with PSF/resolution recovery and TOF — plus attenuation/scatter/randoms/partial-volume corrections — makes images quantitative, but changes SUV, so serial comparison needs matched (or EARL-harmonized) reconstruction. The partial-volume effect underestimates SUV in structures below ~2–3× FWHM (recovery coefficient < 1) — the physics behind falsely low small-lesion SUV and the CT–emission misregistration artifact behind spurious cardiac defects.

Related Pages

• Physics: Radiation detection & instrumentation, SPECT/PET & hybrid imaging, physics of nuclear medicine (positron range).
• Reference: SUV harmonization (EARL); pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A PET resolution-budget diagram (positron range + non-collinearity + detector size).
• A NECR curve (true/scatter/random vs activity).
• A recovery-coefficient curve (SUV recovery vs lesion size / FWHM).

Self-Check

Quick Answer

Long-axial-field-of-view (LAFOV) / total-body PET scanners extend axial coverage from the conventional ~15–26 cm to ~1–2 metres, imaging most or all of the body simultaneously. Combined with digital (SiPM) detectors, this yields a ~10–40× sensitivity gain, which can be "spent" three ways: ultra-low radiation dose, ultra-fast scans (whole-body in seconds–minutes), or very delayed / long-duration dynamic imaging. It uniquely enables total-body dynamic imaging with whole-body kinetic modelling (parametric images) and makes low-activity or short-half-life tracers newly practical. The trade-offs are cost, footprint, and data volume.

Background & the Sensitivity Physics

A conventional PET scanner detects coincidences only within its short axial FOV, so most emitted photons from outside that window are lost. Extending the axial FOV to cover the whole body at once captures a far larger solid angle of coincidences — sensitivity scales steeply (roughly with the square of axial length for a point at the center). Digital SiPM detectors add better timing resolution (TOF), count-rate handling, and spatial resolution. Net effect: an order-of-magnitude-plus increase in detected signal per unit activity.

What the Sensitivity Buys (choose one)

• Ultra-low dose: diagnostic images at a fraction of standard activity — valuable for pediatrics, pregnancy-adjacent decisions, and serial/longitudinal studies.
• Ultra-fast imaging: whole-body acquisition in seconds to a couple of minutes — helps unwell or motion-prone patients and boosts throughput.
• Delayed / long-duration imaging: very late time points (better tumor-to-background for slow-clearing tracers) or long dynamic acquisitions.

Unique Capabilities

• Total-body dynamic imaging: simultaneous time–activity curves for every organ, enabling whole-body kinetic modelling and parametric (e.g., Patlak Ki) images — quantitative physiology across systems at once.
• Low-activity / short-half-life tracers: agents previously impractical become feasible.
• Systems/multi-organ research: inter-organ tracer kinetics, immunology, and drug distribution.

Clinical & Research Applications

• Oncology staging/response at low dose or high speed; better detection of small/low-avidity lesions from higher counts.
• Pediatric imaging with markedly reduced dose.
• Theranostics/dosimetry research (whole-body kinetics).
• Cardiac, inflammation, and neuro dynamic studies.

Limitations

• High capital cost, large footprint, and massive datasets (storage/reconstruction/AI pipelines).
• Availability is limited; most sites still use conventional-axial scanners.
• Realizing benefits requires protocol redesign (dose, timing, dynamic frameworks).

Board Pearls

Long-axial-FOV / total-body PET covers ~1–2 m of the body at once and, with digital SiPM detectors, gains ~10–40× sensitivity. That gain is spent as ultra-low dose, ultra-fast scans, or delayed/long dynamic imaging — and uniquely enables total-body dynamic imaging with whole-body kinetic modelling / parametric images.

Sensitivity rises steeply with axial length because far more coincidence photons are captured. Practical wins: low-dose pediatric/serial imaging, seconds-to-minutes whole-body scans, and feasibility of low-activity or short-half-life tracers.

Constraints are cost, footprint, and data volume, and benefits require protocol redesign rather than dropping old protocols onto new hardware. Digital PET (SiPM) also improves TOF timing and resolution independent of axial length — the two advances are complementary.

Related Pages

• Physics: PET/SPECT performance & reconstruction, SUV harmonization & EARL; tracer: FDG; safety: pediatric dosimetry (low-dose relevance).

Figure / Diagram Suggestions

• An axial-FOV comparison (conventional ~20 cm vs LAFOV ~1–2 m) with the sensitivity curve.
• A "spend the sensitivity" triad (low dose / fast / delayed-dynamic).
• A total-body Patlak parametric concept image (whole-body kinetics).

Self-Check

Quick Answer

SPECT reconstructs a 3D distribution from gamma-camera projections acquired around the patient; PET reconstructs from coincidence lines of response. Both require attenuation and scatter correction for quantitative accuracy — now supplied by the CT of hybrid scanners, which also adds anatomic localization. PET/CT is standard in oncology; SPECT/CT improves localization/characterization of equivocal foci; PET/MR adds soft-tissue contrast at lower radiation.

Reconstruction

Modern systems use iterative reconstruction (e.g. OSEM) rather than filtered back-projection, incorporating models of system physics — resolution recovery / point-spread-function (PSF) modeling and, for PET, TOF — to improve signal-to-noise. Reconstruction settings affect quantitation, which is why SUV must be compared only across matched protocols.

Corrections That Make Images Quantitative

• Attenuation correction (AC): photons are absorbed/scattered en route to the detector; the CT provides an attenuation map. Misregistration between CT and emission data (motion, respiration) creates classic artifacts (anterior/lateral cardiac defects).
• Scatter correction: removes mispositioned scattered photons that reduce contrast.
• Partial-volume effect: small structures (below ~2–3× system resolution) have underestimated activity — a key limit on small-lesion SUV.
• Randoms/dead-time (PET) and decay/attenuation corrections complete the quantitative chain.

Hybrid Modalities

The Corrections That Make Numbers Trustworthy

Attenuation and scatter correction are what turn a picture into a quantitative study; the hybrid CT supplies the attenuation map and the anatomic overlay in one step. Its predictable failure mode is CT–emission misregistration from motion/respiration — the classic cause of a spurious anterior/lateral cardiac "defect."

Why SUV Is Not Portable

SUV depends on reconstruction (algorithm, iterations, PSF), uptake time, glucose, cross-calibration, and — for small lesions — the partial-volume effect. Compare SUV only within matched protocols, ideally the same scanner; use a harmonized (EARL) reconstruction for cross-site or serial quantitation (see the SUV-harmonization page).

Choosing the Hybrid Modality

• SPECT/CT shines at localizing/characterizing equivocal foci (bone, parathyroid, DOTATATE/PSMA SPECT, cardiac-amyloid confirmation).
• PET/CT is the whole-body oncologic and cardiac-flow workhorse.
• PET/MR trades throughput for superior soft-tissue contrast and lower radiation (pelvic, brain, pediatric).

Reporting / Practice Impact

• State the reconstruction/AC method and any misregistration limitation.
• Interpret small-lesion SUV with the partial-volume caveat.
• Use SPECT/CT to reclassify equivocal planar foci (frequently changes management).
• For serial/quantitative work, keep technique constant or use harmonized reconstruction.

Common Pitfalls

• CT/emission misregistration artifacts from motion/respiration (classic on cardiac PET).
• Over-reading small-lesion SUV without accounting for partial-volume underestimation.
• Comparing SUVs across different scanners/reconstructions as if equivalent.
• Assuming an AC-only image is artifact-free — always review the non-AC images too (AC can introduce artifacts).

Board Pearls

Attenuation and scatter correction make images quantitative, and the hybrid CT does double duty (attenuation map + anatomic overlay). The predictable failure mode is CT–emission misregistration (motion/respiration) — the classic spurious anterior/lateral cardiac defect; always review non-AC images alongside AC.

SUV is protocol-dependent (reconstruction/PSF, uptake time, glucose, cross-calibration) and, for small lesions, subject to the partial-volume effect (structures below ~2–3× resolution are underestimated). Compare like with like; use EARL-harmonized reconstruction across sites/serial scans.

Choose the hybrid to the task: SPECT/CT for localizing/characterizing equivocal foci; PET/CT for whole-body oncology and cardiac flow; PET/MR for soft-tissue contrast and lower dose. Iterative reconstruction (OSEM) with PSF/resolution recovery and TOF improves signal-to-noise but also changes SUV — another reason quantitation must be protocol-matched.

Related Pages

• Related: Radiation detection & instrumentation, physics of nuclear medicine, SUV harmonization (EARL).
• Pitfalls: Pearls, pitfalls & normal variants; calculator: SUV tool.

Figure / Diagram Suggestions

• An iterative-reconstruction loop schematic (forward/back projection with system model).
• A misregistration artifact teaching pair (AC vs non-AC cardiac images).
• A hybrid-modality selector (SPECT/CT vs PET/CT vs PET/MR by task).

Self-Check (Board-Style)

Quick Answer

SUV (standardized uptake value = tissue activity concentration ÷ injected activity/body weight) is only meaningful compared like-with-like, yet it varies with scanner, reconstruction, uptake time, glucose, and calibration. Harmonization — most formally through EARL (EANM Research Ltd) accreditation — standardizes acquisition and reconstruction so SUV is comparable across scanners, sites, and serial studies. This underpins response assessment (PERCIST), multicenter trials, and any quantitative/AI use of SUV. The operational rule: never attribute an SUV change to biology when it may be a reconstruction or protocol difference.

Why SUV Drifts

• Reconstruction — algorithm, iterations/subsets, post-filter, resolution recovery, and point-spread-function (PSF) modeling all change SUVmax substantially (sharper reconstructions raise SUVmax).
• Uptake time — FDG SUV rises over ~60–90 min; a 10-min timing difference shifts values.
• Blood glucose and injected-activity/weight accuracy (extravasation, residual in syringe, clock errors).
• Scanner cross-calibration with the dose calibrator must be current.
• Partial-volume effect underestimates small-lesion SUV; SUVpeak (a fixed ~1-cm³ volume) is more reproducible than the single-voxel SUVmax.

The Metrics

Harmonization in Practice

• EARL defines phantom-based (NEMA image-quality) performance limits and reconstruction settings; accredited sites produce comparable SUVs. Many sites run a harmonized (EARL-compliant) reconstruction alongside their sharpest clinical reconstruction — the sharp one for detection, the harmonized one for quantification.
• For response assessment, hold technique constant across a patient's serial scans — ideally the same scanner and protocol — and use a consistent reference region (liver for PERCIST, with blood pool as backup).
• Newer PSF/ultra-high-resolution reconstructions raise SUV, so a harmonized series is used specifically for quantitative comparison; EARL2 standards accommodate PSF-era scanners.

Worked Point

A lesion reads SUVmax 8.0 on an old OSEM reconstruction and 11.0 on a new PSF reconstruction of the same acquisition. That +38% is pure reconstruction, not tumor progression — comparing them as if equivalent would falsely call progressive disease. Compare the harmonized-to-harmonized series instead.

Reporting Checklist

• State the reconstruction used (and whether a harmonized reconstruction was applied for quantitation).
• Report the metric (SUVmax vs SUVpeak/SUL) and the reference region.
• For serial studies, confirm same scanner/protocol/uptake time; flag any change.

Common Pitfalls

• Attributing an SUV change to biology when it reflects a reconstruction/protocol difference.
• Comparing a PSF/sharp reconstruction to an older harmonized one.
• Ignoring partial-volume underestimation in small lesions.
• Uncorrected extravasation or timing errors inflating apparent change.

Board Pearls

SUV is only meaningful compared like-with-like, yet it drifts with scanner, reconstruction (PSF/iterations/filter), uptake time, glucose, and calibration. Harmonization — formally via EARL accreditation — standardizes acquisition/reconstruction so SUV is comparable across scanners, sites, and serial studies (many sites run a harmonized reconstruction alongside their sharpest clinical one). For response assessment (PERCIST), hold technique constant and use a consistent liver reference.

Sharper reconstructions raise SUVmax — a PSF series can read 30–40% higher than OSEM on the same data, mimicking progression. SUVpeak/SUL are more reproducible than the noisy single-voxel SUVmax, and PERCIST uses SULpeak normalized to lean body mass with a liver reference.

Keep the drift sources straight: reconstruction and uptake time dominate, partial-volume underestimates small lesions, and cross-calibration/extravasation silently bias values. Never attribute an SUV change to biology when it may be a protocol difference — the whole point of EARL is to remove that ambiguity for multicenter and longitudinal work.

Related Pages

• Tracer: FDG; reporting: oncology response criteria (RECIST/PERCIST); physics: PET/SPECT performance & reconstruction.

Figure / Diagram Suggestions

• A same-data, two-reconstruction SUV comparison (OSEM vs PSF) showing the artifactual rise.
• A drift-source fishbone (reconstruction, timing, glucose, calibration, partial volume).

Self-Check

Quick Answer

Nuclear medicine is organized less by organ than by what a tracer targets. This compendium is a single interactive view of the field's molecular toolkit: every major radiopharmaceutical mapped to its isotope, imaging or therapeutic modality, biological mechanism, molecular target, and primary use. Filter by mechanism class (perfusion, metabolism, receptor, antigen, transporter, bone, and so on) or by modality (PET, SPECT, therapy), search by target or indication, and click any agent to open its full page. It is the fastest way to see the whole landscape at once — and to grasp the mechanism-based logic that makes the field coherent.

How to use it

Read the table as a map of mechanism, not anatomy. Agents that share a mechanism class behave alike wherever they are used: transporter tracers (iodide via NIS, MIBG via the norepinephrine transporter, ioflupane via DAT, FDOPA via the catecholamine pathway) all exploit a specific uptake pump; receptor/antigen tracers (DOTATATE→SSTR, PSMA ligands, FES→ER) bind a molecular target that also defines a matched therapy; perfusion agents trace blood flow; metabolism agents trace a metabolic pathway. Seeing tracers grouped this way is what turns a long list of names into a system — and it is why every future radiopharmaceutical slots into an existing mechanism class.

Reading the theranostic pairs

The compendium makes the theranostic pairs visible at a glance: an imaging tracer and a therapy that share the same target. SSTR imaging (⁶⁸Ga-DOTATATE) pairs with ¹⁷⁷Lu-DOTATATE therapy; PSMA imaging pairs with ¹⁷⁷Lu- and ²²⁵Ac-PSMA; NIS imaging (radioiodine) pairs with ¹³¹I therapy; the norepinephrine transporter pairs ¹²³I-MIBG imaging with ¹³¹I-MIBG therapy. The principle is universal: the therapy can only treat what the imaging agent shows expresses the target — which is why target-negative disease (detected by a second tracer such as FDG) predicts treatment failure.

Self-Check

Key References

• SNMMI/EANM procedure guidelines for the individual agents listed; radiopharmaceutical target/mechanism reviews.
• The mechanism-based organization mirrors this atlas's Domain II (Probes & Targets) framework.

Quick Answer

A radiopharmaceutical pairs a radionuclide (signal/therapy source) with a targeting molecule (which determines biodistribution). Radionuclides come from generators (a long-lived parent decays to a short-lived daughter eluted on demand — Mo-99/Tc-99m, Ge-68/Ga-68, Sr-82/Rb-82), from cyclotrons (F-18, I-123, Cu-64, and many PET tracers), or from reactors (Mo-99 parent, I-131, Lu-177). Most Tc-99m agents are made on site by adding eluted pertechnetate to a cold kit, then verified by radiochemical purity testing before release.

Clinical Importance

Supply logistics shape practice: generator half-lives dictate elution schedules, cyclotron products must be produced/distributed within tight windows, and Mo-99 supply disruptions periodically threaten Tc-99m availability. Production also underpins quality — a mislabeled or impure preparation produces artifacts or non-diagnostic studies.

Sources of Radionuclides

Generator Equilibria

• Transient equilibrium (parent half-life modestly longer than daughter): Mo-99 (66 h) → Tc-99m (6 h) — daughter activity regrows between elutions and slightly exceeds a simple parent-tracking curve.
• Secular equilibrium (parent half-life vastly longer): Ge-68 → Ga-68, Sr-82 → Rb-82 — daughter activity equals parent activity at equilibrium and the generator lasts a long time.

The Mo-99 / Tc-99m Generator

Tc-99m is the SPECT workhorse (140 keV γ, 6-hour half-life). Its Mo-99 parent (66 h) is eluted as pertechnetate; the daughter regrows between elutions. Elutions are tested for Mo-99 breakthrough (parent contamination) and aluminum (from the column). Pertechnetate is then combined with cold kits to make MDP, sestamibi, MAG3, MAA, sulfur colloid, and others.

Cold Kits & Labeling

A cold kit contains the ligand plus a reducing agent (stannous ion) in a sterile vial; adding Tc-99m-pertechnetate reduces and complexes the technetium to make the labeled agent. Labeling failures leave recognizable signatures:

• Free pertechnetate (incomplete reduction / oxidation): thyroid, stomach, salivary activity.
• Hydrolyzed-reduced technetium (excess stannous / hydrolysis): a liver/colloid pattern.

Quality Control

Before release: radiochemical purity (correct labeled species, e.g. by chromatography), radionuclidic purity (Mo-99 breakthrough, aluminum for the Tc generator), sterility/apyrogenicity for compounded products, and activity in a dose calibrator. PET and therapy radiopharmaceuticals have their own release specifications, and particle-size control matters for MAA and sulfur colloid (aggregates cause artifactual uptake).

Practical Supply Notes

• Ga-68 generators make site-flexible PSMA/DOTATATE PET; F-18 analogs allow centralized batch distribution.
• Short half-lives force rapid, sometimes real-time release testing.
• Mo-99 is reactor-produced with a fragile supply chain — periodic shortages force protocol substitutions.

Common Pitfalls

• Attributing a labeling artifact to disease (gastric free-pertechnetate mistaken for pathology).
• Ignoring Mo-99 breakthrough or aluminum limits on generator eluate.
• Particle-size problems (MAA/sulfur colloid) causing artifactual distribution.
• Assuming any PET tracer can be shipped — short-half-life agents (C-11, N-13, O-15) cannot.

Board Pearls

A generator holds a longer-lived parent that decays into a shorter-lived, useful daughter eluted on demand (daughter regrows between elutions) — how cyclotron-free sites make Tc-99m (Mo-99), Ga-68 (Ge-68), and Rb-82 (Sr-82). Distinguish transient (Mo-99/Tc-99m) from secular (Ge-68/Ga-68, Sr-82/Rb-82) equilibrium.

Two labeling-failure patterns to know cold: free pertechnetate → thyroid/stomach/salivary activity; hydrolyzed-reduced technetium → a liver/colloid pattern. Recognizing these prevents calling an artifact disease and prompts a repeat preparation.

Before release, preparations are checked for radiochemical purity (correct labeled species), radionuclidic purity (Mo-99 breakthrough, aluminum), and — for compounded/PET products — sterility/endotoxin, with short half-lives forcing rapid release testing. Particle-size control matters for MAA/sulfur colloid, and Ga-68 generators vs F-18 distribution explains site-flexible vs centralized PET supply.

Related Pages

• Related: Physics of nuclear medicine, radiation detection & instrumentation, PET radiochemistry & production, molecular imaging & the theranostic pair.
• Pitfalls: Pearls, pitfalls & normal variants (free-pertechnetate signature).

Figure / Diagram Suggestions

• A Mo-99/Tc-99m generator diagram (column, elution, regrowth curve).
• Transient vs secular equilibrium activity curves.
• A labeling-artifact plate (free pertechnetate vs hydrolyzed-reduced colloid pattern).

Self-Check (Board-Style)

Quick Answer

Molecular imaging visualizes a specific biological target — a receptor, transporter, enzyme, or metabolic pathway — rather than anatomy. When the same targeting molecule can carry either a diagnostic isotope (to see the target) or a therapeutic isotope (to treat it), the two form a theranostic pair. Target biology determines everything downstream: which patients express the target, how avidly (receptor density), and whether therapy is likely to work.

The Conceptual Spine

Every established radionuclide therapy rests on a molecular target with sufficient, selective expression: PSMA on prostate cancer, SSTR2 on neuroendocrine tumors, the sodium-iodide symporter in thyroid tissue, the norepinephrine transporter in catecholamine tumors, CD20 on B-cell lymphoma. Imaging the target first is what converts radionuclide therapy from empiric to selected — the diagnostic scan predicts where the therapeutic dose will deposit.

The "See It, Treat It" Loop

1. Image the target (Ga-68/Cu-64/I-123 diagnostic).
2. Confirm adequate, selective expression (uptake thresholds).
3. Treat the same target (Lu-177/Y-90/I-131/α-emitter).
4. Verify delivery and monitor response (post-therapy imaging, dosimetry).

The imaging and therapy are two ends of one molecular decision.

Why Receptor Density & Heterogeneity Matter

Uptake intensity is a surrogate for target expression, and expression predicts response. That is why the Krenning score (SSTR uptake ≥ liver) gates PRRT and why adequate PSMA avidity gates ¹⁷⁷Lu-PSMA. Tumors are heterogeneous, so dual-tracer phenotyping (SSTR + FDG, or PSMA + FDG) captures dedifferentiated, target-low clones (FDG-positive / target-negative) that predict poorer response — a more complete picture than any single agent.

From Imaging to a "Responsible Physician" Discipline

Because imaging and therapy are two ends of one molecular decision, the physician delivering theranostics owns the whole arc: target confirmation, patient selection, dosimetry, toxicity, and longitudinal follow-up — not just the infusion. This framing is explicit in the field's education and consensus literature.

The Chemistry That Enables Pairing

The DOTA chelator is the practical linchpin of metal-based theranostics: the same ligand carries a diagnostic radiometal (Ga-68, Cu-64) or a therapeutic one (Lu-177, Y-90, or an α-emitter) with near-identical biodistribution. Non-metal PET labels (F-18, C-11) attach by covalent chemistry instead. This interchangeability is what makes "see it, treat it" a single molecular decision rather than two unrelated tests.

Established & Emerging Targets

Common Pitfalls

• Treating a molecular target as uniformly expressed across all lesions in a patient.
• Selecting for therapy on anatomy alone without confirming target avidity.
• Ignoring discordant (FDG-positive / target-negative) disease that limits benefit.

Board Pearls

Because tracer uptake tracks target expression, and expression predicts response, imaging quantifies who will benefit from therapy — the Krenning score (SSTR ≥ liver) gates PRRT, adequate PSMA avidity gates ¹⁷⁷Lu-PSMA. Patient selection for radioligand therapy is an imaging decision, not just a histologic one.

Tumors are heterogeneous, so dual-tracer phenotyping (SSTR + FDG, PSMA + FDG) exposes dedifferentiated, target-low clones (FDG-positive / target-negative) that predict poorer response — a single scan can look "eligible" while a discordant clone quietly limits benefit.

The DOTA chelator is the linchpin: the same ligand carries a diagnostic radiometal (Ga-68/Cu-64) or a therapeutic one (Lu-177/Y-90/α) with near-identical biodistribution, while non-metal labels (F-18, C-11) attach covalently. This interchangeability makes "see it, treat it" one molecular decision, and it generalizes to emerging targets (FAP, DLL3) — only the ligand and isotope change.

Related Pages

• Tracers: PSMA PET agents, DOTATATE PET agents, FDG.
• Therapy: Theranostics overview and the specific radioligand-therapy pages.
• Related: Radiopharmaceuticals & production, physics of nuclear medicine.

Figure / Diagram Suggestions

• The "see it, treat it" loop (image → confirm → treat → verify).
• A DOTA chelator cartoon carrying interchangeable diagnostic/therapeutic radiometals.
• A dual-tracer heterogeneity panel (target-avid vs FDG-avid discordant clones).

Self-Check (Board-Style)

Quick Answer

A radiopharmaceutical's behavior — where it goes, what it means, and whether it can be paired with a therapeutic isotope — follows from its uptake mechanism and molecular target. Grouping tracers by mechanism (metabolic trapping, active transport, receptor binding, physical microembolization, chemisorption, blood-pool retention) makes their normal biodistribution, characteristic artifacts, and theranostic potential predictable rather than memorized. This page organizes the atlas's tracers by mechanism and draws the clinical consequence of each.

Why Mechanism Predicts Everything Downstream

The same property that produces the signal produces the physiologic biodistribution (hence the normal-variant "mimics"), the labeling-failure pattern, and the eligibility logic for therapy. A tracer taken up by the sodium-iodide symporter images the thyroid and free pertechnetate lands in stomach/salivary tissue and the therapeutic isotope of the same handling (I-131) treats iodine-avid disease — one mechanism, three consequences.

Metabolic Trapping

Active Transport

Receptor / Antigen Binding

Physical / Compartmental Mechanisms

The Theranostic Corollary

A mechanism is a theranostic pair when the same targeting handling can carry a diagnostic and a therapeutic isotope: NIS (I-123 → I-131), SSTR2 (Ga-68-DOTATATE → ¹⁷⁷Lu-DOTATATE), PSMA (Ga-68/¹⁸F → ¹⁷⁷Lu/²²⁵Ac), NET/uptake-1 (I-123-MIBG → I-131-MIBG), CD20 (antibody + ⁹⁰Y), and — emerging — CAIX (⁸⁹Zr → ¹⁷⁷Lu-girentuximab) and FAP. The DOTA chelator is what makes the metal-based pairs interchangeable at near-identical biodistribution.

The Artifact Corollary

A tracer's normal biodistribution is its artifact list. Free-pertechnetate labeling failures reproduce the NIS/gastric/salivary map; DOTATATE's physiologic uncinate/spleen/adrenal/pituitary uptake mimics tumor; PSMA's celiac ganglion/salivary/renal uptake mimics nodes; MAA's clumping or a right-to-left shunt sends activity systemically. Knowing the mechanism is knowing the false positive.

The Extraction & Kinetics Corollary

Mechanism sets quantitative behavior: high-extraction tubular MAG3 images poor kidneys where filtered DTPA fails; Rb-82/Tl extraction falls at high flow (a kinetic-modeling correction in MFR); sestamibi/HMPAO show minimal redistribution (flexible timing / injection-snapshot), unlike thallium (redistribution = viability). These are not trivia — they determine which agent answers a given question.

Related Pages

• Foundational: Molecular imaging & the theranostic pair, radiopharmaceuticals & production, physics of nuclear medicine.
• Applied: the individual tracer pages linked from each row.

Figure / Diagram Suggestions

• A mechanism → biodistribution → artifact → theranostic four-column synthesis.
• A theranostic-pair ladder (target → diagnostic isotope → therapeutic isotope).

Self-Check

Quick Answer

PET tracers are built by attaching a positron-emitting radionuclide to a targeting molecule, then verifying purity before release. F-18 (110 min) is cyclotron-produced and attached by nucleophilic/electrophilic substitution (e.g., FDG), enabling batch distribution. C-11 (20 min) is added by rapid methylation but needs an on-site cyclotron. Ga-68 (68 min) comes from a generator and is attached via DOTA-type chelators to peptides (DOTATATE, PSMA). Cu-64 (12.7 h) is a cyclotron product allowing delayed imaging and shipping. The governing principle: half-life sets the logistics, and the chelator enables theranostics.

The Main PET Radionuclides

Positron range matters for resolution: F-18's low positron energy (~0.6-mm mean range) gives the sharpest images; Ga-68 and Rb-82 have larger ranges that modestly blur resolution.

How the Radionuclides Are Made

• Cyclotron: accelerates protons/deuterons into a target — e.g., ¹⁸O(p,n)¹⁸F produces F-18 as fluoride in enriched water; N-13, C-11, O-15 similarly.
• Generator: a long-lived parent decays to a short-lived daughter that is eluted on demand — Ge-68 (271 d) → Ga-68 (cyclotron-free PET), analogous to the Mo-99/Tc-99m and Sr-82/Rb-82 generators.

Chelators & Small-Molecule Labeling

Radiometals (Ga-68, Cu-64, and therapeutic Lu-177/Y-90/Ac-225) are bound by bifunctional chelators — DOTA is the workhorse for theranostic pairs because the same chelator on the same targeting peptide carries the diagnostic Ga-68 or the therapeutic Lu-177. Non-metal PET nuclides (F-18, C-11) are attached by covalent organic chemistry (substitution, methylation). Molar (specific) activity — radioactive fraction of total ligand — must be high enough to avoid saturating a receptor target (critical for peptide agents).

Quality Control (Before Release)

• Radiochemical purity (desired species vs free radionuclide/impurities) — affects image quality and dosimetry.
• Radionuclidic purity (e.g., Ge-68 breakthrough in Ga-68 eluate).
• Chemical purity (residual solvents), pH, sterility/endotoxin, and activity/molar activity.
• Short half-lives drive rapid, sometimes real-time (post-release) testing.

Reporting / Practice Notes

• Match the agent's half-life to the clinical logistics (on-site vs shipped).
• For receptor agents, ensure adequate molar activity to avoid target saturation.
• Document lot QC (purity, pH, endotoxin) per the tracer's monograph.

Common Pitfalls

• Assuming any PET tracer can be shipped — C-11/N-13/O-15 cannot.
• Overlooking radiochemical-purity limits (free F-18 → bone/stomach uptake; free Ga-68 → altered biodistribution).
• Ignoring Ge-68 breakthrough in generator eluate.
• Low molar activity saturating a peptide receptor and blunting uptake.

Board Pearls

PET tracers attach a positron emitter to a targeting molecule, and half-life sets the logistics: F-18 (110 min) and Cu-64 (12.7 h) support batch distribution; C-11 (20 min), N-13 (10 min), and O-15 (2 min) require on-site production; Ga-68 comes from a generator (cyclotron-free access to PSMA/DOTATATE PET). The theranostic idea is DOTA chelation — the same bifunctional chelator carries diagnostic Ga-68 or therapeutic Lu-177 on the same molecule: image, then treat.

F-18's low positron range (~0.6 mm) gives the sharpest images; Ga-68 and Rb-82 have larger ranges that modestly blur resolution. Molar (specific) activity must be high enough to avoid saturating a peptide receptor target.

Production splits into cyclotron (¹⁸O(p,n)¹⁸F; N-13/C-11/O-15) and generator (Ge-68→Ga-68, like Mo-99→Tc-99m and Sr-82→Rb-82). QC before release checks radiochemical, radionuclidic, and chemical purity, pH, sterility/endotoxin, and activity — with Ge-68 breakthrough the specific generator concern and free F-18 revealing itself as bone/gastric uptake. Short half-lives force real-time release testing.

Related Pages

• Tracers: FDG, DOTATATE, PSMA; therapy chelation: theranostics pages; physics: counting statistics, radiation biology & protection.

Figure / Diagram Suggestions

• A cyclotron vs generator production schematic (F-18 target vs Ge-68/Ga-68 elution).
• A DOTA theranostic pair cartoon (Ga-68 image ↔ Lu-177 treat, same peptide).
• A positron-range vs resolution comparison (F-18 vs Ga-68 vs Rb-82).

Self-Check

Quick Answer

Beyond the clinical mainstays (FDG, PSMA, DOTATATE, FDOPA, FES, FAPI), several target-specific PET tracers are established in research and selected practice: hypoxia tracers (F-18-FMISO, FAZA, HX4, Cu-ATSM) for radiotherapy dose-painting and prognosis; proliferation (F-18-FLT) for early treatment response; CXCR4 (Ga-68-pentixafor, with a pentixather therapy pair) for hematologic/marrow disease; GRPR/bombesin (e.g., RM2) for prostate/breast; and amino-acid tracers (C-11-methionine, F-18-FET) for brain tumors (and myeloma). Most are investigational, and each targets a distinct tumor biology that complements glucose metabolism.

Hypoxia Imaging

• Agents: F-18-FMISO (the prototype nitroimidazole), F-18-FAZA (faster clearance, better contrast), F-18-HX4, and Cu-60/61/62/64-ATSM.
• Mechanism: nitroimidazoles are reduced and trapped only in hypoxic, viable cells (bioreductive retention); ATSM is retained under reducing/hypoxic conditions.
• Use: map tumor hypoxia (a driver of radioresistance) for RT dose-painting and prognosis in head-and-neck, lung, and other tumors. Limitation: low tumor-to-background contrast and slow kinetics (FMISO), reproducibility.

Proliferation Imaging

• F-18-FLT (fluorothymidine): trapped by thymidine kinase-1 (TK1), reflecting DNA-synthesis / proliferation rather than glucose metabolism.
• Use: early treatment-response assessment (proliferation falls before size). Limitation: high physiologic liver and bone-marrow uptake (it images marrow proliferation), limiting abdominal/marrow reads.

CXCR4 — an Emerging Theranostic Pair

• Ga-68-pentixafor images the CXCR4 chemokine receptor, highly expressed in some lymphomas, multiple myeloma, marrow-based disease, and other tumors.
• Theranostic potential: the therapeutic analog pentixather (Lu-177/Y-90) — an image-and-treat pathway under investigation for hematologic malignancy.

GRPR / Bombesin

• Gastrin-releasing-peptide-receptor ligands (e.g., RM2) target prostate and breast cancer (GRPR is often expressed where PSMA is low, and in ER+ breast). Theranostic development is ongoing; a potential complement to PSMA in prostate cancer.

GLP-1 Receptor (Exendin) — Insulinoma

• Ga-68 / F-18-exendin (a GLP-1-receptor agonist) targets the GLP-1 receptor, densely expressed on benign insulinomas — which are often small and SSTR-variable (DOTATATE-negative). Exendin/GLP-1R imaging is the emerging nuclear localizer for the occult insulinoma that eludes DOTATATE and cross-sectional imaging, complementing EUS and selective arterial calcium-stimulation sampling.

Amino-Acid Tracers (Brain & Beyond)

• C-11-methionine (MET) and F-18-FET (fluoroethyltyrosine) are transported by LAT amino-acid transporters, giving low normal cortical background — superior to FDG for brain-tumor delineation, grading, biopsy targeting, and recurrence-vs-radiation-change. C-11-MET also has a role in myeloma and parathyroid. (FDOPA, a related amino-acid tracer, has its own page.)

Where These Fit

Each tracer answers a biology FDG cannot: hypoxia (radioresistance), proliferation (DNA synthesis), receptor expression (CXCR4, GRPR), or amino-acid transport (brain tumor). They are mostly investigational or niche, used where the standard tracers are non-specific, negative, or uninformative — and several carry theranostic ambitions (CXCR4, GRPR, and the alpha/Cu-67 pairs).

Common Pitfalls

• Treating research tracers as validated standard-of-care.
• FLT's intense physiologic marrow/liver uptake obscuring those regions.
• Hypoxia tracers' low contrast and reproducibility limits.
• Assuming a target is present without confirmation (receptor expression varies).

Board Pearls

Beyond the mainstays, key research/niche PET tracers target biology FDG misses: hypoxia (FMISO/FAZA/HX4/Cu-ATSM — nitroimidazole bioreductive trapping, for RT dose-painting/radioresistance), proliferation (F-18-FLT via TK1, for early response), CXCR4 (pentixafor, with a pentixather therapy pair), GRPR/bombesin (prostate/breast), and amino-acid tracers (C-11-MET, F-18-FET) for brain tumors.

F-18-FET / C-11-methionine have low normal cortical background, outperforming FDG for brain-tumor grading, biopsy targeting, and recurrence-vs-radiation-change. F-18-FLT images proliferation but has high physiologic marrow/liver uptake (it also marks marrow proliferation).

CXCR4 (pentixafor → pentixather) and GRPR (RM2) are emerging theranostic pairs — image-and-treat pathways for hematologic and prostate/breast disease. Hypoxia tracers suffer low tumor-to-background contrast; ATSM images reducing/hypoxic conditions. Most of these remain investigational as of 2026.

Related Pages

• Tracers: FDG (contrast metabolism), FDOPA (amino-acid), FAPI (stroma); disease: head & neck cancer (hypoxia/dose-painting), multiple myeloma (CXCR4/MET), brain tumor PET (amino-acid).

Figure / Diagram Suggestions

• A biology-by-tracer map (glucose/FDG vs hypoxia/proliferation/receptor/amino-acid).
• A nitroimidazole bioreductive-trapping hypoxia cartoon.
• A CXCR4/GRPR theranostic-pair schematic (image → treat).

Self-Check

Quick Answer

Pertechnetate is the unbound generator eluate — it is trapped but not organified by the thyroid, and taken up by gastric mucosa, salivary glands, and choroid plexus. This biodistribution underlies its uses: thyroid uptake/scan (trapping only), the Meckel scan (ectopic gastric mucosa), salivary scintigraphy, first-pass angiography, and dacryoscintigraphy. Recognizing physiologic pertechnetate distribution is also the key to spotting free-pertechnetate labeling artifacts on other Tc-99m studies.

Mechanism

Pertechnetate behaves like iodide at the sodium-iodide symporter (trapping) but is not organified (no incorporation into thyroid hormone). It is also concentrated by gastric mucosa and salivary glands and by choroid plexus — the biologic basis of both its indications and its artifacts.

Biodistribution

Thyroid, salivary glands, stomach, choroid plexus, blood pool, and urinary excretion. (For Meckel imaging, perchlorate can block choroid-plexus/thyroid uptake, and cimetidine reduces mucosal washout.)

Clinical Indications

• Thyroid scan/uptake (trapping function — hot/cold nodules, ectopic/lingual thyroid, thyroiditis pattern); the discordant pertechnetate-hot / radioiodine-cold nodule is a recognized trap.
• Meckel scan (ectopic gastric mucosa; cimetidine augmentation).
• Salivary scintigraphy (function/duct patency; Sjögren, post-radioiodine xerostomia).
• Dacryoscintigraphy (lacrimal drainage); first-pass/shunt studies; brain-death/flow studies (historical, BBB-dependent).

The Free-Pertechnetate Artifact

The physiologic pertechnetate map — thyroid, stomach, salivary glands — is identical to the free-pertechnetate artifact that appears when any other Tc-99m agent is poorly labeled. Recognizing that pattern prevents calling a labeling problem "disease" and prompts a repeat preparation.

Reporting Checklist

• Thyroid: state that pertechnetate reflects trapping (not organification); describe nodule pattern / ectopic tissue.
• Meckel: a focus mirroring the stomach in timing/intensity (RLQ); augmentation used.
• Salivary: uptake and duct-mediated excretion (± sialagogue).
• Distinguish physiologic gastric/salivary/choroid-plexus activity from pathology.

Common Pitfalls

• Mistaking normal gastric/salivary/choroid-plexus activity for pathology.
• Attributing a labeling artifact on another study to disease rather than free pertechnetate.
• Overlooking the discordant nodule (pertechnetate-hot but radioiodine-cold) in autonomy assessment.

Board Pearls

Pertechnetate behaves like iodide at the sodium-iodide symporter — trapped but not organified — so a thyroid pertechnetate scan reflects trapping function, not hormone synthesis (a difference from radioiodine). It also concentrates in gastric mucosa, salivary glands, and choroid plexus — exactly the uses (thyroid, Meckel, salivary) and artifacts it explains.

The physiologic pertechnetate map (thyroid/stomach/salivary) is the same pattern as the free-pertechnetate artifact seen when other Tc-99m agents are poorly labeled — recognizing it prevents calling a labeling problem disease.

For Meckel imaging, cimetidine reduces mucosal washout (highest-yield augmentation) and perchlorate can block thyroid/choroid-plexus uptake; a rare pertechnetate-hot / radioiodine-cold discordant nodule is a trap in autonomy assessment (organification-defect nodules trap but do not organify).

Related Pages

• Related: GI bleeding & Meckel scans, hyperthyroidism / thyroid nodule (thyroid uptake), esophageal/reflux/salivary studies.
• Radiopharmacy: Radiopharmaceuticals & production (free-pertechnetate artifact).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A trapping-vs-organification thyroid schematic (pertechnetate vs radioiodine).
• The physiologic pertechnetate map = free-pertechnetate artifact overlay.
• A Meckel RLQ focus mirroring the stomach.

Self-Check (Board-Style)

Quick Answer

Tc-99m-sulfur colloid is phagocytosed by the reticuloendothelial system (RES) — Kupffer cells (liver), spleen, and bone marrow — and, when filtered to small particles, drains via lymphatics. This gives it a wide range of uses: liver–spleen and bone-marrow imaging, sentinel-node lymphoscintigraphy, labeling the gastric-emptying meal, LeVeen/peritoneovenous shunt patency, and rapid GI-bleeding detection. Particle size determines destination.

Mechanism

Colloidal particles are cleared by phagocytosis; biodistribution depends on particle size — larger particles favor liver/spleen, smaller (filtered) particles reach marrow and drain through lymphatics to the first-draining node. This one principle explains the agent's many roles.

Biodistribution

Liver (~85%), spleen, and marrow. Colloid shift (increased spleen/marrow relative to liver) indicates hepatocellular dysfunction or portal hypertension. Large aggregates (poor preparation) can cause lung uptake.

Clinical Indications

• Liver–spleen imaging: FNH (Kupffer cells → normal/increased uptake), colloid shift, accessory spleen/splenosis (with heat-damaged RBCs).
• Bone-marrow imaging: paired with labeled-WBC studies to separate marrow from infection (see infection page).
• Sentinel-node mapping (melanoma, breast) — filtered colloid (or tilmanocept alternative).
• Gastric-emptying meal label; LeVeen (peritoneovenous) shunt patency; GI bleed (rapid; less common than RBC).

Protocol Notes

• Sentinel node: filter the colloid to small particles for lymphatic migration; intradermal/peritumoral injection; SPECT/CT for aberrant basins.
• Liver–spleen: standard colloid; heat-damaged RBCs are splenic-specific for accessory spleen/splenosis.
• Marrow: compare distribution against labeled-WBC in periprosthetic infection.

Interpretation Highlights

• FNH: contains Kupffer cells → normal/increased colloid uptake (helps separate from adenoma/malignancy, which are photopenic).
• Colloid shift: hepatocellular dysfunction/portal hypertension.
• Marrow vs infection: incongruent WBC (positive) / marrow (negative) = infection (see infection & inflammation page).

Reporting Checklist

• Describe liver/spleen/marrow distribution and any colloid shift.
• For FNH, note Kupffer-cell uptake distinguishing it from adenoma/malignancy.
• For sentinel node, report drainage basins and node number (SPECT/CT).
• Note poor-preparation lung uptake if present.

Common Pitfalls

• Poor preparation / large aggregates causing lung uptake artifacts.
• Confusing physiologic marrow uptake with pathology on whole-body colloid studies.
• Using unfiltered colloid for sentinel-node work (poor lymphatic migration).

Board Pearls

Sulfur colloid is phagocytosed by the RES, and particle size decides where it goes: larger particles favor liver/spleen (liver–spleen imaging), smaller (filtered) particles reach marrow and drain through lymphatics (marrow imaging and sentinel-node mapping). One agent, many applications, all from that principle.

Colloid shift (spleen/marrow > liver) flags hepatocellular dysfunction/portal hypertension; FNH shows Kupffer-cell colloid uptake (distinguishing it from adenoma/malignancy); heat-damaged RBCs are splenic-specific for accessory spleen/splenosis.

In periprosthetic infection, sulfur-colloid marrow imaging paired with labeled WBC is the crux: congruent = marrow (no infection), incongruent (WBC-positive/marrow-negative) = infection. Sulfur colloid also labels the standardized gastric-emptying meal and assesses LeVeen-shunt patency — while large aggregates from poor preparation cause artifactual lung uptake.

Related Pages

• Related: Liver–spleen & hemangioma imaging, lymphoscintigraphy & sentinel node, infection & inflammation (marrow imaging), gastric emptying.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A particle-size → destination schematic (liver/spleen vs marrow/lymphatics).
• A colloid-shift teaching pair (normal vs cirrhosis/portal hypertension).
• A WBC + marrow congruence plate (infection vs marrow).

Self-Check (Board-Style)

Quick Answer

Tc-99m-labeled red blood cells remain in the intravascular blood pool, supporting three main studies: MUGA/gated blood-pool LVEF, hepatic hemangioma characterization (perfusion–blood-pool mismatch with delayed fill-in), and lower GI bleeding localization (activity that appears and moves within the bowel lumen). Labeling quality is critical — in-vitro methods give the highest efficiency and least free pertechnetate.

Labeling Methods

Stannous-ion pretreatment (reduces technetium so it binds intracellular hemoglobin) then Tc-99m:

Drug interference (heparin, some medications, prior iodinated contrast, circulating antibodies) can reduce labeling.

Biodistribution

Blood pool (heart, great vessels, liver, spleen). Poor labeling leaves free pertechnetate → thyroid/stomach/salivary activity (an artifact and a sensitivity-reducer).

Clinical Indications

• MUGA / equilibrium radionuclide angiography: reproducible, count-based LVEF (cardiotoxicity monitoring — see MUGA page).
• Hepatic hemangioma: characteristic delayed blood-pool fill-in (near-specific with SPECT for lesions > ~1.5–2 cm).
• GI bleeding: sensitive to ~0.1–0.2 mL/min; can image intermittent bleeding over an extended window.

Interpretation Highlights

• Hemangioma: decreased/normal perfusion on flow phase but progressive fill-in on delayed blood-pool imaging (perfusion–blood-pool mismatch).
• GI bleed: true hemorrhage appears and moves; a fixed focus is a vascular structure/varix, not active bleeding — localize by the earliest focus.

Reporting Checklist

• MUGA: LVEF (method/reference), regional wall motion, labeling adequacy, rhythm.
• Hemangioma: flow vs delayed blood-pool pattern; note partial-volume limit for small lesions.
• GI bleed: presence/appears-and-moves, earliest site of origin, rate/intermittency.

Common Pitfalls

• Poor labeling (drug interactions, technique) → free pertechnetate and reduced sensitivity.
• Small hemangiomas (< ~1.5 cm) below SPECT resolution (partial-volume).
• Calling fixed intravascular/varix activity as active GI bleeding.

Board Pearls

Labeled red cells stay intravascular, underpinning three uses: MUGA (reproducible count-based LVEF for cardiotoxicity surveillance), hepatic hemangioma (near-specific perfusion–blood-pool mismatch with delayed fill-in on SPECT), and lower GI bleeding (activity that appears and moves within the bowel).

In-vitro labeling maximizes efficiency and minimizes the free-pertechnetate artifact (thyroid/stomach/salivary) — preferred for bleed studies; drug interference (heparin, prior contrast) can degrade labeling.

On a hemangioma study, small lesions (< 1.5 cm) fall below SPECT resolution (partial-volume); on a bleed study, a fixed focus is a vascular structure/varix, not active hemorrhage — localize by the earliest moving focus, since later distributed activity may have migrated far from the source.

Related Pages

• Protocols: MUGA, GI bleeding & Meckel scans, liver–spleen & hemangioma imaging.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A labeling-method comparison (in vitro vs modified in vivo vs in vivo).
• A hemangioma flow-vs-delayed fill-in teaching pair.
• An appears-and-moves bleed sequence vs a fixed vascular focus.

Self-Check (Board-Style)

Quick Answer

Tc-99m-DTPA is cleared by glomerular filtration, making it the agent for GFR measurement (camera-based Gates method or plasma clearance) and an alternative for dynamic renography. Its lower extraction than MAG3 gives poorer images in impaired renal function, so MAG3 is preferred when function is reduced. As a nebulized aerosol it also serves as a V/Q ventilation agent, and its bolus is used for radionuclide angiography/flow studies.

Mechanism

DTPA is freely filtered at the glomerulus and neither secreted nor reabsorbed — a true filtration marker (hence GFR). Its single-pass extraction is lower than MAG3's (which is actively secreted), so DTPA gives higher background and poorer images when renal function is impaired.

Biodistribution

Kidneys/collecting system and bladder; higher soft-tissue background than MAG3. As an aerosol, deposition in the airways/alveoli (central "hot spots" in obstruction).

Clinical Indications

• GFR quantification: Gates camera method or plasma-sampling clearance.
• Dynamic renography where MAG3 is unavailable (less ideal in renal impairment).
• Aerosol ventilation for V/Q (central deposition in airflow obstruction).
• Radionuclide angiography / flow (transplant perfusion, brain-death flow — crosses a disrupted blood–brain barrier).

MAG3 vs DTPA (Quick Contrast)

Reporting Checklist

• GFR: report the method (Gates vs plasma clearance) and split GFR where relevant.
• Renography: curve/drainage as per the renal-scintigraphy protocol (prefer MAG3 in poor function).
• Ventilation: note central "hot-spot" deposition in obstruction.

Common Pitfalls

• Using DTPA in significant renal impairment (poor target-to-background) instead of MAG3.
• Aerosol clumping artifacts in COPD (central hot spots).
• Extravasated injection invalidating GFR's injected-dose reference (Gates).

Board Pearls

DTPA is cleared by glomerular filtration — not secreted or reabsorbed — making it a true GFR marker (Gates camera method or plasma clearance). Its lower single-pass extraction than MAG3 means poorer images in impaired function, so MAG3 is preferred when renal function is reduced.

As a nebulized aerosol, DTPA is a V/Q ventilation agent (central "hot spots" in airflow obstruction); as a bolus it serves radionuclide angiography/flow (transplant perfusion, brain-death flow).

The unifying theme is a small, freely-filtered, non-reabsorbed molecule. It crosses a disrupted blood–brain barrier (historical brain-flow use), and its filtration handling is exactly why it measures GFR while MAG3 (tubular) better reflects effective renal plasma flow and images better in CKD.

Related Pages

• Tracer/protocol: MAG3, renal scintigraphy, GFR measurement; ventilation: ventilation agents, V/Q scan & PE.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A filtration-vs-secretion nephron schematic (DTPA vs MAG3).
• A Gates-method GFR calculation diagram.
• An aerosol central-deposition COPD teaching image.

Self-Check (Board-Style)

Quick Answer

Three USP chapters govern how drugs are compounded: ⟨795⟩ non-sterile, ⟨797⟩ sterile, and ⟨825⟩ radiopharmaceuticals — the chapter written specifically for nuclear pharmacy. USP ⟨825⟩ is the controlling standard for preparing, compounding, dispensing, and repackaging radiopharmaceuticals, harmonizing sterility/quality with the realities of short half-lives and radiation safety (it recognizes that release often precedes full sterility testing and balances ALARA against aseptic technique). It defines beyond-use dates (BUDs), air-quality/engineering-control requirements, and categories such as immediate-use preparation.

Why a Radiopharmaceutical-Specific Chapter

General sterile-compounding rules (⟨797⟩) assume time for sterility testing and don't address radiation. Radiopharmaceuticals are short-lived (a Tc-99m or F-18 dose can't wait days for sterility results) and radioactive (ALARA competes with prolonged aseptic manipulation). ⟨825⟩ was created to reconcile these — it applies sterile-compounding principles while accommodating decay and radiation safety, and it is the standard nuclear pharmacy follows.

The Three Chapters

A related chapter — not a compounding one. USP ⟨800⟩ (Hazardous Drugs — Handling in Healthcare Settings) governs containment and handling, not compounding, so it is not one of the three compounding chapters above. It still applies to radiopharmaceuticals that are also hazardous drugs (e.g. some therapy agents), and is considered alongside ⟨825⟩ for those.

Core ⟨825⟩ Concepts

• Categories of activity: preparation (per manufacturer kit instructions), compounding (altering/combining beyond labeling), dispensing, and repackaging — each with requirements.
• Immediate-use provisions for urgent, short-turnaround doses (limited, defined conditions).
• Engineering controls: appropriate primary engineering control (PEC) and shielded workspace; air quality suited to the manipulation.
• Beyond-use dating (BUD): the date/time after which a preparation must not be used — driven by sterility risk and radiochemical stability, alongside physical decay.
• Quality/QC: radiochemical/radionuclidic purity, and documentation, integrated with radiation-safety practice.

Beyond-Use Date vs Expiration

BUD is assigned by the compounder based on stability and sterility risk of the specific preparation; a manufacturer expiration date applies to the original product. For radiopharmaceuticals, the usable window is often bounded by decay as much as sterility.

Practice Notes

• Follow ⟨825⟩ as the operative standard for radiopharmaceutical preparation/compounding; use ⟨797⟩ principles for asepsis and ⟨795⟩ for any non-sterile components.
• Match engineering controls and air quality to the manipulation performed.
• Assign and document BUDs; integrate ALARA with aseptic technique.

Common Pitfalls

• Applying ⟨797⟩ alone to radiopharmaceuticals without ⟨825⟩'s radiation/decay accommodations.
• Confusing BUD (compounder-assigned, stability/sterility) with manufacturer expiration.
• Overlooking immediate-use conditions/limits.
• Ignoring ⟨800⟩ for radiopharmaceuticals that are also hazardous drugs.

Board Pearls

Three USP chapters govern compounding — ⟨795⟩ non-sterile, ⟨797⟩ sterile, ⟨825⟩ radiopharmaceuticals — and ⟨825⟩ is the controlling standard for radiopharmaceutical preparation/compounding/dispensing/repackaging. It exists because general sterile rules assume time for sterility testing and ignore radiation, whereas radiopharmaceuticals are short-lived (release often precedes full testing) and radioactive (ALARA vs prolonged asepsis).

A beyond-use date (BUD) is assigned by the compounder from stability/sterility risk (distinct from the manufacturer's expiration); for radiopharmaceuticals the window is often bounded by decay. Immediate-use provisions allow urgent short-turnaround doses under defined limits.

⟨825⟩ distinguishes preparation (per kit instructions), compounding (beyond labeling), dispensing, and repackaging, each with engineering-control and air-quality requirements matched to the manipulation. Radiopharmaceuticals that are also hazardous drugs additionally invoke ⟨800⟩ containment.

Related Pages

• Physics: Radiation biology & protection; radiopharmacy: PET radiochemistry & production; safety: Radiation safety & patient release.

Figure / Diagram Suggestions

• A 795/797/825 scope Venn (non-sterile / sterile / radiopharmaceutical, with 800 overlap).
• A BUD-vs-expiration-vs-decay timeline for a Tc-99m dose.

Self-Check

Quick Answer

Iodine radioisotopes are trapped by the sodium-iodide symporter (NIS) and then organified into thyroid hormone, making them both diagnostic (uptake and scan) and therapeutic agents. I-123 (pure γ 159 keV, 13-h half-life, no beta) is preferred for diagnostic uptake and imaging; I-131 (β⁻ + γ 364 keV, 8-day half-life) is used for therapy — hyperthyroidism and differentiated thyroid-cancer remnant ablation/treatment — and for post-therapy whole-body scanning. Two board-defining concepts: trapping vs organification (why a rare nodule is pertechnetate-hot but iodine-cold), and the iodine-load trap (recent iodine suppresses uptake).

Mechanism

NIS actively co-transports iodide (with sodium) into the thyroid follicular cell — trapping — driven by the Na⁺/K⁺-ATPase gradient. Trapped iodide is then organified by thyroid peroxidase (TPO) onto tyrosine residues of thyroglobulin to form hormone. Pertechnetate (Tc-99m) is trapped by NIS but not organified, which is why a nodule can be pertechnetate-hot yet radioiodine-cold (discordant) — a discordant nodule carries malignancy concern and warrants further evaluation. I-131's beta emission (mean ~190 keV, mm-range) delivers the therapeutic dose to trapping tissue; its 364-keV gamma is imaged but degrades resolution and drives radiation-safety precautions.

Biodistribution

Thyroid (target), plus salivary glands, gastric mucosa (NIS-expressing), and urinary excretion; the nasopharynx and lactating breast also express NIS. Functioning differentiated thyroid-cancer metastases concentrate iodine — the basis of post-therapy whole-body scanning and I-131 therapy of iodine-avid disease. Physiologic bowel and bladder activity are common whole-body-scan mimics.

Physics

I-123's pure gamma and short half-life give lower thyroid dose and cleaner images; I-131's beta makes it therapeutic but its long half-life and high-energy gamma raise dose and require patient-release precautions.

Clinical Indications

• Thyroid uptake & scan (I-123): differentiate causes of hyperthyroidism (Graves vs toxic nodular vs thyroiditis) and assess nodule function (hot vs cold).
• I-131 therapy for hyperthyroidism: Graves disease, toxic nodular goiter.
• I-131 for differentiated thyroid cancer: remnant ablation, treatment of iodine-avid disease, and post-therapy whole-body scans.

Preparation & Protocol

• Screen for a recent iodine load — iodinated CT contrast, amiodarone, kelp/supplements — and defer if present (measure urinary iodine if unsure).
• Exclude pregnancy (absolute contraindication for therapy) and address lactation (NIS in breast; stop breastfeeding).
• For cancer studies/therapy, achieve TSH stimulation by thyroid-hormone withdrawal or recombinant human TSH (Thyrogen), often with a low-iodine diet.
• Uptake measurement at standardized times (e.g., 4–6 h and 24 h) against a reference standard.

Interpretation Highlights

• In thyrotoxicosis, the uptake value sorts the differential: high uptake (Graves, toxic nodular) is radioiodine-treatable; low uptake (thyroiditis, exogenous hormone, iodine load) is not — nothing is concentrating iodine.
• A discordant nodule (pertechnetate-hot, iodine-cold) is suspicious and should not be called benignly "hot."
• Functioning metastases on whole-body scan guide cancer therapy; correlate with thyroglobulin.

Reporting Checklist

• Report percent uptake with the timing and reference range.
• State the iodine-load / medication history and pregnancy status.
• For therapy, document written directive, activity, TSH-stimulation method, and radiation-safety/patient-release measures (I-131 at higher activities).

Common Pitfalls

• Iodine load (CT contrast, amiodarone, kelp/supplements) suppressing uptake — can invalidate a study or reduce therapy efficacy.
• Inadequate TSH stimulation (insufficient withdrawal or rhTSH) reducing cancer-therapy uptake.
• Pregnancy/lactation not excluded before administration.
• Misreading physiologic salivary/gastric/bowel/bladder activity on whole-body scans as disease.

Board Pearls

Iodide is trapped by the sodium-iodide symporter (NIS) and then organified by thyroid peroxidase. Pertechnetate is trapped but not organified — so a rare nodule is pertechnetate-hot yet radioiodine-cold (discordant), a finding that raises malignancy concern. Use I-123 for diagnosis (pure gamma, best dosimetry/images) and I-131 for therapy (its beta delivers the dose).

In thyrotoxicosis the uptake sorts the differential: high uptake (Graves, toxic nodular) is radioiodine-treatable; low uptake (thyroiditis, exogenous hormone, iodine load) is not — there is nothing concentrating iodine. Always screen for a recent iodine load (contrast, amiodarone, kelp) that competes for NIS and suppresses uptake.

For differentiated thyroid cancer, TSH stimulation (withdrawal or rhTSH) plus a low-iodine diet maximizes uptake; functioning metastases on the post-therapy whole-body scan are the basis for I-131 therapy of iodine-avid disease. Pregnancy is an absolute contraindication to therapy; I-131's long half-life and 364-keV gamma drive patient-release rules (≤ ~5 mSv to others / activity or dose-rate thresholds).

Related Pages

• Disease: Hyperthyroidism, Thyroid nodule, Thyroiditis.
• Related: pertechnetate thyroid imaging; radiation safety & patient release.

Figure / Diagram Suggestions

• A NIS trapping → TPO organification cell schematic (with the pertechnetate "trapped-not-organified" branch).
• A high-vs-low uptake thyrotoxicosis decision tree.
• An I-123 vs I-131 property/role comparison table.

Self-Check

Quick Answer

The radioiodine (or pertechnetate) uptake and scan distinguishes the causes of thyrotoxicosis by pattern: diffusely increased in Graves, focal/heterogeneous in toxic nodular disease, and low in thyroiditis or exogenous hormone. High-uptake causes are radioiodine-treatable; low-uptake thyrotoxicosis is not (nothing concentrates the iodine). In Graves, the therapeutic goal is a controlled hypothyroid endpoint — a randomized trial found fixed activity (typically 10–15 mCi) produced fewer treatment failures than titrating to euthyroidism.

Background & Pathophysiology

Thyrotoxicosis presents identically across causes but demands opposite management. Imaging answers the pivotal mechanistic question: is the gland making too much hormone (high uptake — Graves' TSH-receptor antibody stimulation, or autonomous nodules) or leaking/receiving it (low uptake — destructive thyroiditis, exogenous hormone, iodine load)?

Clinical & Laboratory

Suppressed TSH with elevated free T4/T3. Graves-specific features: orbitopathy, pretibial myxedema, thyroid bruit, and positive TRAb/TSI. Toxic nodular disease occurs in older patients with long-standing goiter. Check ESR/CRP (subacute thyroiditis) and thyroglobulin (low in exogenous).

Uptake Patterns

Doppler: hypervascular "thyroid inferno" in Graves vs low flow in destructive thyroiditis.

Radioiodine Therapy

• Graves: aim to render the patient hypothyroid (a controlled, easily treated endpoint), not euthyroid. A randomized trial found fixed activity (10–15 mCi) gave fewer treatment failures than dose-titration to euthyroidism; calculated dosing also performs well.
• Toxic nodular disease: calculated dosing is generally preferred — autonomous nodules concentrate iodine while the suppressed normal gland is relatively spared (lower post-treatment hypothyroidism than Graves).
• Pre-treatment: exclude pregnancy/lactation; avoid iodine load; consider orbitopathy risk (radioiodine can worsen active Graves ophthalmopathy — steroid cover or alternative therapy in moderate/severe eye disease, especially smokers).
• Safety: counsel on patient-release precautions.

Interpretation & Decision

High uptake vs low uptake decides everything. High-uptake Graves/nodular disease → I-131 or surgery or antithyroid drugs; low-uptake thyroiditis/exogenous → supportive only. Confirm no iodine load first (falsely low uptake).

Differential Diagnosis

Graves, toxic adenoma, toxic MNG, subacute/painless/postpartum thyroiditis, exogenous/factitious thyrotoxicosis, iodine-induced (Jod-Basedow), amiodarone types 1/2, struma ovarii, and rare TSH-secreting adenoma.

Reporting Checklist

• Report the RAIU value (timing/reference) and the scan pattern.
• Classify as radioiodine-treatable (high uptake) vs not (low uptake).
• For therapy, document written directive, activity, pregnancy exclusion, and orbitopathy risk.

Common Pitfalls

• Treating thyroiditis as Graves (wasted therapy).
• Not checking for an iodine load before uptake (falsely low uptake).
• Radioiodine in active moderate/severe Graves orbitopathy without steroid cover (can worsen eye disease).
• Radioiodine in children under ~5 (avoided; careful activity in ages 5–10).

Board Pearls

The uptake-and-scan pattern separates thyrotoxicosis into radioiodine-treatable and not: diffuse ↑ = Graves, focal ↑ with suppressed background = toxic nodular disease (both treatable); low/absent uptake = thyroiditis, exogenous hormone, or iodine load — the gland is leaking or loaded, not making, so there is no target for I-131. Always check for a recent iodine load first.

In Graves, aim for hypothyroidism (a controlled endpoint) — a randomized trial found fixed activity (10–15 mCi) gave fewer failures than titrating to euthyroidism. In toxic nodular disease, calculated dosing spares the suppressed normal gland (less post-treatment hypothyroidism).

Radioiodine can worsen active Graves orbitopathy — use steroid cover or an alternative in moderate/severe eye disease, especially smokers. Avoid I-131 in young children, pregnancy/lactation, and after an iodine load. Doppler "thyroid inferno" supports Graves when antibodies are equivocal.

Related Pages

• Tracer: Radioiodine (I-123/I-131); diseases: Thyroiditis, Thyroid nodule.

Figure / Diagram Suggestions

• A three-pattern uptake plate (diffuse Graves / focal toxic nodule / low thyroiditis).
• A fixed vs calculated dosing decision aid (Graves vs nodular).

Self-Check

Quick Answer

Thyroiditis causes thyrotoxicosis by releasing preformed hormone from an inflamed, damaged gland — not by overproduction — so radioiodine uptake (RAIU) is low, the mirror image of Graves disease. Recognizing this pattern prevents inappropriate I-131: there is no trapping tissue to treat. Management is supportive (beta-blockade; NSAIDs/steroids for the painful subacute form) through an often triphasic course (thyrotoxic → hypothyroid → recovery). Always exclude a recent iodine load and exogenous thyroid hormone, which also produce low-uptake thyrotoxicosis.

Background & Pathophysiology

Thyroiditis is destructive/inflammatory thyroid injury that spills stored T4/T3 into the circulation. Because the follicular cells are damaged and TSH is suppressed, iodine trapping falls — hence low RAIU. The subtypes:

• Subacute (de Quervain / granulomatous): often painful, post-viral, with elevated ESR/CRP; typically triphasic and self-limited.
• Painless / silent (a variant of autoimmune thyroiditis) and postpartum thyroiditis: painless, antibody-associated, often triphasic.
• Amiodarone-induced thyrotoxicosis type 2 (destructive; low uptake, low vascularity on Doppler) — contrast with type 1 (iodine-induced overproduction in nodular glands).
• Hashimoto (chronic lymphocytic): usually hypothyroid, but can have an early hashitoxicosis phase.

Clinical & Laboratory

Thyrotoxic symptoms (palpitations, tremor, heat intolerance) identical to Graves, but without ophthalmopathy/pretibial myxedema. Labs: suppressed TSH, elevated free T4/T3; elevated ESR/CRP and tender gland in subacute; TPO antibodies in autoimmune forms; a low or normal thyroglobulin is expected in factitious (exogenous) thyrotoxicosis, distinguishing it from true thyroiditis.

Imaging Role

The RAIU / pertechnetate scan sorts the thyrotoxicosis differential:

Color-flow Doppler complements uptake: low vascularity in destructive thyroiditis (and AIT type 2) vs the "thyroid inferno" hypervascularity of Graves.

Interpretation & Decision

A low RAIU in a thyrotoxic patient means the gland is leaking or loaded, not making — do not give I-131. Confirm there is no recent iodinated contrast/amiodarone/kelp, and consider exogenous hormone (check thyroglobulin — low in factitious). Anticipate the hypothyroid phase; most patients recover, though postpartum/silent forms may leave permanent hypothyroidism.

Differential Diagnosis

Graves disease (high uptake, orbitopathy), toxic nodular disease (focal uptake), exogenous/factitious thyrotoxicosis (low thyroglobulin), iodine-induced (Jod-Basedow), struma ovarii (pelvic uptake, absent neck uptake), and amiodarone type 1 vs type 2.

Reporting Checklist

• State the RAIU value with timing/reference range and the scan pattern (low/absent).
• Note Doppler vascularity if performed (low in destructive forms).
• Explicitly flag that low uptake is not a radioiodine indication; recommend supportive management.
• Document iodine-load/medication history.

Common Pitfalls

• Treating thyroiditis as Graves — wasted, ineffective radioiodine.
• Missing exogenous levothyroxine or iodine load as the cause of low-uptake thyrotoxicosis.
• Overlooking the hypothyroid phase and stopping surveillance early.
• Conflating amiodarone type 1 (iodine-induced, treat the overproduction) with type 2 (destructive, steroids).

Board Pearls

Thyroiditis causes thyrotoxicosis by releasing preformed hormone from an inflamed gland, not by overproduction — so RAIU is low, the mirror image of Graves. That single finding prevents inappropriate I-131 (nothing is trapping iodine to treat). Management is supportive (beta-blockade; NSAIDs/steroids for pain) through an often triphasic self-limited course.

Always exclude a recent iodine load and exogenous hormone, which also suppress uptake — check thyroglobulin (low in factitious/exogenous thyrotoxicosis). Doppler shows low vascularity in destructive thyroiditis vs the "thyroid inferno" of Graves.

Distinguish amiodarone-induced thyrotoxicosis type 2 (destructive, low uptake/low vascularity, steroid-responsive) from type 1 (iodine-induced overproduction in nodular glands). Consider struma ovarii when the neck uptake is absent but the patient is thyrotoxic (ectopic thyroid tissue concentrates iodine in the pelvis).

Related Pages

• Tracer: Radioiodine (I-123/I-131); diseases: Hyperthyroidism, Thyroid nodule.

Figure / Diagram Suggestions

• A low-uptake vs Graves diffuse-uptake teaching pair.
• A triphasic thyroiditis timeline (thyrotoxic → hypothyroid → recovery).
• A Doppler "low-flow destructive" vs "thyroid inferno" comparison.

Self-Check

Quick Answer

The radionuclide uptake/scan answers one question about a thyroid nodule: is it autonomously functioning ("hot")? When TSH is low/suppressed, a scan showing a hyperfunctioning nodule (tracer-avid with suppressed surrounding gland) essentially excludes malignancy for that nodule and redirects management toward treating hyperthyroidism (I-131 or surgery) rather than biopsy. Non-functioning ("cold") or indeterminate nodules — and any nodule with normal/high TSH — are evaluated by ultrasound risk stratification (TI-RADS) and FNA, not scintigraphy.

Background

Thyroid nodules are extremely common and mostly benign. The malignancy question is stratified by ultrasound features and cytology; the nuclear scan has a narrow but decisive role — identifying an autonomous (Plummer) nodule in a patient whose TSH is suppressed, which reclassifies the nodule as functional (and almost never malignant) and moves care to the hyperthyroidism pathway.

The TSH Gate

• Low/suppressed TSH: obtain an uptake scan. A hot nodule is almost never malignant and generally does not need FNA; manage as toxic adenoma/toxic MNG.
• Normal/high TSH: a functional scan adds little — proceed with ultrasound (TI-RADS) + FNA by size/risk thresholds.
• A cold nodule is nonspecific (most nodules are cold; most cold nodules are still benign) — it requires US/FNA assessment.

Imaging & Cytology Integration

• Ultrasound (TI-RADS / ACR): composition, echogenicity, margins, shape (taller-than-wide), and echogenic foci (microcalcifications) set the FNA threshold.
• FNA (Bethesda categories): the definitive risk step for cold/indeterminate nodules; molecular testing refines indeterminate (Bethesda III/IV) results.
• Scintigraphy: reserved for the suppressed-TSH scenario to confirm autonomy.

Interpretation & Decision

The scan's value is ruling in autonomy in a low-TSH patient — that finding largely excludes cancer and avoids an unnecessary biopsy, shifting to definitive hyperthyroidism therapy. It does not stratify malignancy risk in a euthyroid patient; there, ultrasound and FNA govern.

Differential Diagnosis

Benign colloid/adenomatous nodule, autonomous (toxic) adenoma, follicular adenoma vs carcinoma (cytology cannot distinguish — architecture on histology does), papillary carcinoma (US features), and the discordant nodule (pertechnetate-hot but radioiodine-cold).

Reporting Checklist

• State the TSH context and whether the nodule is hot, warm, or cold, with the suppressed-background finding for autonomy.
• For hot nodules with low TSH, note that FNA is generally unnecessary and recommend the hyperthyroidism pathway.
• For cold/indeterminate, defer to US risk category + FNA.
• Document iodine-load history (invalidates uptake).

Common Pitfalls

• Ordering an uptake scan for a euthyroid nodule (low yield) instead of ultrasound/FNA.
• Using the scan to "clear" a nodule when TSH is normal — it does not stratify risk there.
• Misreading a discordant nodule (pertechnetate-hot, radioiodine-cold) — a recognized autonomy-assessment trap.
• Recent iodine load suppressing uptake and invalidating the study.

Board Pearls

The radionuclide scan answers one question: is the nodule autonomously functioning ("hot")? With low/suppressed TSH, a hot nodule (tracer-avid, suppressed background) is almost never malignant — it excludes cancer for that nodule and redirects care to the hyperthyroidism pathway (I-131 or surgery), sparing an FNA. With normal/high TSH the functional scan adds nothing: use ultrasound (TI-RADS) + FNA.

A cold nodule is nonspecific — most nodules are cold and most are still benign — so it always needs US/FNA, not reassurance from the scan. Pertechnetate imaging can mislead: a discordant nodule is pertechnetate-hot but radioiodine-cold (trapped, not organified) and should not be called autonomous.

The scan rules in autonomy, it does not rule out cancer in the euthyroid setting. Bethesda cytology (with molecular testing for indeterminate results) and TI-RADS drive the malignancy pathway; scintigraphy's role is confined to the suppressed-TSH patient. Always exclude a recent iodine load before relying on uptake.

Related Pages

• Tracer: Radioiodine (I-123/I-131); diseases: Hyperthyroidism, Thyroiditis.

Figure / Diagram Suggestions

• A TSH-gated decision tree (low TSH → scan; normal/high TSH → US/FNA).
• A hot vs cold nodule teaching pair (suppressed background in autonomy).

Self-Check

Quick Answer

Differentiated thyroid cancer (papillary and follicular) is managed by surgery followed by risk-stratified radioiodine (I-131) for selected patients, using ATA risk categories. Radioiodine has three distinct intents — remnant ablation, adjuvant treatment of suspected residual disease, and therapy of known iodine-avid disease — each with different activities. Low-risk patients often need no radioiodine (or a low 30 mCi activity); high-risk and metastatic disease receives higher activities. Thyroglobulin is the key tumor marker, and loss of iodine avidity defines RAI-refractory disease — the setting where FDG-PET and systemic therapy take over.

Definition

Differentiated thyroid cancer (DTC) comprises malignancies arising from follicular epithelial cells that retain enough differentiation to handle iodide and produce thyroglobulin: papillary (PTC), follicular (FTC), and oncocytic (Hürthle-cell) carcinomas. This retained iodine biology is what makes DTC uniquely amenable to radioiodine theranostics — and its loss defines refractory disease.

Synonyms

Well-differentiated thyroid carcinoma; papillary thyroid carcinoma (PTC); follicular thyroid carcinoma (FTC); oncocytic (Hürthle-cell) carcinoma. Distinguish sharply from medullary thyroid carcinoma (parafollicular C-cell, non-iodine-avid) and anaplastic carcinoma (dedifferentiated, aggressive).

Epidemiology

DTC is the most common endocrine malignancy and its incidence rose markedly over recent decades, driven substantially by overdiagnosis of small, indolent papillary cancers detected incidentally on neck imaging. There is a female predominance (roughly 3:1). Papillary carcinoma accounts for the large majority (~85–90%), follicular for around 10%, and oncocytic for a small remainder. Overall disease-specific mortality is low, which is why management has shifted toward de-escalation.

Etiology & Risk Factors

• Ionizing radiation to the neck in childhood/adolescence is the best-established environmental cause (e.g. Chernobyl-associated pediatric PTC, often RET/PTC-rearranged).
• Iodine status: deficiency is associated relatively with follicular histology; iodine sufficiency/excess shifts the balance toward papillary.
• Hereditary syndromes: familial adenomatous polyposis / Gardner (cribriform-morular PTC), Cowden / PTEN hamartoma, Carney complex, Werner, and familial nonmedullary thyroid cancer.
• Family history and, for follicular disease, longstanding nodular goiter.

Pathophysiology

DTC growth is driven chiefly by MAPK/ERK-pathway activation (BRAF, RAS, RET/PTC). Critically, well-differentiated tumor cells retain the sodium-iodide symporter (NIS), which traps iodide, and thyroid peroxidase, which organifies it — the basis for both radioiodine imaging and therapy, and for thyroglobulin production as a marker. TSH upregulates NIS, so raising TSH (withdrawal or rhTSH) enhances uptake before therapy. Dedifferentiation — through additional genomic hits and high MAPK output — downregulates NIS, causing loss of iodine avidity (RAI-refractory disease) with a reciprocal increase in glucose metabolism (FDG avidity) — the "flip-flop" phenomenon.

Genetics & Molecular Biology

• BRAF V600E — the commonest PTC driver (classic and tall-cell variants); associated with more aggressive features and, with TERT, worse outcomes; targetable (dabrafenib + trametinib) and a redifferentiation lever.
• RAS mutations — follicular carcinoma and the follicular-pattern lesions (including NIFTP); generally less aggressive.
• RET/PTC rearrangements — radiation-associated and pediatric PTC.
• PAX8–PPARG fusion — follicular carcinoma.
• TERT promoter mutations — mark aggressive behavior and synergize with BRAF/RAS.
• TP53 and additional hits — progression toward poorly-differentiated and anaplastic carcinoma.
• NTRK / ALK / RET fusions — actionable with selective inhibitors (larotrectinib/entrectinib; selpercatinib).

Histopathology

• Papillary carcinoma: diagnosed by nuclear features — enlarged, overlapping, optically clear ("Orphan-Annie-eye") nuclei, nuclear grooves, and intranuclear pseudoinclusions; psammoma bodies are characteristic. Spreads via lymphatics to cervical nodes. Aggressive variants: tall-cell, columnar, hobnail. The noninvasive encapsulated follicular-variant lesion is reclassified as NIFTP (indolent, not called carcinoma).
• Follicular carcinoma: distinguished from a benign adenoma only by capsular and/or vascular invasion (so FNA cannot diagnose it — it requires resection); classified minimally vs widely invasive. Spreads hematogenously (lung, bone).
• Oncocytic (Hürthle-cell) carcinoma: oncocyte-rich; frequently less iodine-avid and more FDG-avid, and more often RAI-refractory.

Clinical Presentation

Most patients present with an asymptomatic thyroid nodule and are euthyroid. Papillary cancer commonly presents with, or develops, cervical lymph-node metastases. Follicular cancer more often presents with distant (lung, bone) metastases. Locally advanced disease may cause hoarseness (recurrent laryngeal nerve), dysphagia, or airway symptoms.

Laboratory Findings

• Thyroglobulin (Tg) with anti-Tg antibodies — after total thyroidectomy and ablation, Tg is the central surveillance marker; anti-Tg antibodies interfere and must be reported alongside.
• TSH — suppressed as therapy in higher-risk disease; stimulated (> 30 mIU/L) before RAI to maximize uptake.
• Calcitonin is not a DTC marker — it belongs to medullary carcinoma (a common conceptual check).

Imaging Findings by Modality

• Ultrasound (TI-RADS): first-line for nodule risk stratification and nodal mapping; guides FNA.
• FNA cytology (Bethesda system): the diagnostic pivot; molecular testing refines indeterminate categories.
• CT / MRI: locally advanced disease, airway/vascular involvement, and distant staging (use non-contrast or plan iodine washout if RAI is anticipated, since iodinated contrast blocks uptake).
• Radioiodine whole-body scan (I-123 or low-activity I-131 diagnostic; and the post-therapy scan): maps iodine-avid remnant, nodal, and distant disease; SPECT/CT localizes and characterizes foci.
• FDG-PET/CT: the key tool in Tg-positive, RAI-scan-negative ("flip-flop") disease and RAI-refractory settings; FDG-avidity is itself an adverse prognostic marker.
• I-124 PET: research/lesional dosimetry and high-resolution detection.

Radiopharmaceutical Uptake Mechanisms

Iodide (and its radioiodine isotopes) is trapped by the NIS at the follicular-cell basolateral membrane and organified by thyroid peroxidase. I-131 delivers therapeutic β-radiation (with an imageable γ for the post-therapy scan); I-123 is a pure-γ diagnostic isotope with better image quality and lower thyroid dose. Tc-99m-pertechnetate is trapped by NIS but not organified, so it images trapping only (and can produce a rare discordant pertechnetate-hot / radioiodine-cold nodule). TSH stimulation and a low-iodine state maximize the target's avidity for radioiodine.

Typical PET Tracers

Typical SPECT / Planar Tracers

Therapy Indications

• Surgery: lobectomy (low-risk, ≤ ~4 cm, unifocal, node-negative) vs total thyroidectomy (higher-risk / bilateral / nodal disease) ± central-compartment dissection.
• Radioiodine (I-131) — the three intents below, chosen by ATA risk.
• TSH suppression with levothyroxine, graded to risk and response.
• External-beam radiotherapy — selective (gross residual/unresectable local disease).
• Systemic therapy for RAI-refractory disease: multikinase inhibitors lenvatinib (SELECT) and sorafenib (DECISION); mutation-selective agents — selpercatinib (RET), larotrectinib/entrectinib (NTRK), dabrafenib + trametinib (BRAF); and redifferentiation (short-course MEK ± BRAF inhibition to restore NIS, then re-treat with I-131).

Radioiodine — The Three Intents

Two randomized trials (ESTIMABL1, HiLo) established 1.1 GBq (30 mCi) as non-inferior to 3.7 GBq for remnant ablation in low/intermediate-risk disease, and ESTIMABL2 / IoN support omission of ablation in selected low-risk patients.

Preparation (that makes or breaks the treatment)

• TSH stimulation (goal typically > 30 mIU/L) via thyroid-hormone withdrawal or recombinant human TSH (rhTSH) — rhTSH spares hypothyroid symptoms with equivalent ablation and better quality of life.
• Low-iodine diet and exclusion of recent iodinated contrast and amiodarone, which compete for uptake and can waste the therapy (measure urinary iodine when in doubt rather than guess).
• Pregnancy excluded; lactation ceased and the breast involuted (the lactating breast concentrates iodine).

Dosimetry Approaches

Most DTC therapy uses fixed/empiric activities. Dosimetry-guided approaches are used for challenging cases — extensive metastatic disease, renal impairment, pediatric patients, and to respect the classic blood/marrow (~2 Gy) and lung-retention safety limits (to avoid radiation pneumonitis/fibrosis in diffuse pulmonary metastases). I-124 PET or serial I-131 measurements support lesion-level dosimetry.

Post-Therapy Imaging & Stunning

A post-therapy whole-body scan (± SPECT/CT), performed a few days after the therapeutic activity, detects avid disease missed on diagnostic imaging and upstages a meaningful fraction — often the study that changes management. Thyroid stunning — reduced uptake of the therapy activity caused by a preceding higher-activity diagnostic I-131 dose — is mitigated by using I-123 or low-activity I-131 for diagnostic scans and treating promptly.

RAI-Refractory Disease

Defined (Dadu/Cabanillas-type framework) by any of: no iodine uptake at known disease, progression despite documented uptake, progression within a year of therapy, or persistent disease after high cumulative activity. High MAPK-pathway output associates with loss of avidity, and these tumors typically become FDG-avid (flip-flop). Management pivots from more radioiodine (which does not distinguish responders and only adds toxicity) to systemic therapy and redifferentiation.

Differential Diagnosis

• Benign nodule / adenoma (FTC needs invasion on histology to separate from a follicular adenoma).
• Medullary thyroid carcinoma — non-iodine-avid, calcitonin-secreting; do not attempt an RAI pathway.
• Anaplastic carcinoma — dedifferentiated, FDG-avid, non-iodine-avid, fulminant.
• Primary thyroid lymphoma (often on a background of Hashimoto).
• Metastasis to the thyroid (e.g. renal cell) and parathyroid lesions.

Reporting Checklist

• State diagnostic vs post-therapy scan, isotope and activity, and TSH-stimulation method.
• Localize uptake as remnant (thyroid bed) vs nodal vs distant, using SPECT/CT for equivocal foci.
• Correlate with stimulated Tg and anti-Tg-antibody status.
• Note physiologic uptake and contamination mimics (salivary, nasopharyngeal, gastric, hepatic, bladder, skin contamination).
• For refractory work-up, integrate FDG-PET findings and the flip-flop pattern.

Prognosis & Dynamic Risk Stratification

Overall prognosis is excellent. AJCC staging is age-dependent (a threshold at 55 years reflects the strong age effect on mortality). Beyond initial ATA risk (low/intermediate/high), the modern approach is dynamic response-to-therapy restratification — excellent, indeterminate, biochemical-incomplete, or structural-incomplete response — which updates prognosis and tailors TSH-suppression intensity and surveillance over time. FDG-avidity and TERT/BRAF co-mutation mark higher-risk biology.

Board Pearls

Radioiodine has three distinct intents — remnant ablation, adjuvant, and therapy — and the activity follows the intent and the ATA risk category. Name the intent before the number. For low/intermediate-risk ablation, 30 mCi is non-inferior to 100 mCi (HiLo, ESTIMABL1), and ablation can be omitted in selected low-risk patients (ESTIMABL2, IoN).

The post-therapy whole-body scan finds disease diagnostic scans miss and upstages patients — always review it. Avoid stunning by using I-123 or low-activity I-131 for diagnostic imaging.

RAI-refractory disease is the flip-flop point: dedifferentiating tumors lose NIS (iodine-negative) and gain glucose metabolism (FDG-positive). Escalating cumulative I-131 does not distinguish responders and only adds toxicity — the levers become multikinase inhibitors (lenvatinib/SELECT, sorafenib/DECISION), mutation-selective agents (selpercatinib for RET; larotrectinib/entrectinib for NTRK; dabrafenib+trametinib for BRAF), and redifferentiation (MEK ± BRAF inhibition to restore uptake, then re-treat with I-131).

Related Pages

• Tracer: Radioiodine (I-123 / I-131) — Thyroid (trapping/organification, dosimetry, precautions).
• Contrast disease: Medullary thyroid carcinoma (non-iodine-avid; FDOPA/DOTATATE/FDG).
• Nodule workup: Thyroid nodule evaluation and Hyperthyroidism (uptake patterns).
• Calculators: Decay, Dosimetry, Effective dose.

Figure / Diagram Suggestions

• NIS trapping / organification cartoon showing TSH upregulation and the effect of an iodine load.
• A three-intents decision graphic (ablation vs adjuvant vs therapy) mapped to ATA risk and activity.
• The flip-flop concept illustrated: differentiated (I-131-avid, FDG-low) → dedifferentiated (I-131-negative, FDG-high).
• Annotated post-therapy WBS normal-variant / contamination plate.

Self-Check (Board-Style)

Quick Answer

Differentiated thyroid cancer is managed by two complementary risk frameworks. AJCC/TNM staging (age-dependent) predicts mortality. The ATA initial risk stratification (low / intermediate / high) predicts recurrence and drives the radioiodine decision and TSH-suppression target. Because initial risk is a static estimate, it is updated over time by dynamic response-to-therapy restratification — excellent, indeterminate, biochemical-incomplete, or structural-incomplete response — which continuously refines prognosis and de-escalates or intensifies follow-up.

Two Questions, Two Systems

• How likely is this to be lethal? → AJCC/TNM stage (mortality). A key quirk: staging is age-dependent, with a threshold at 55 years reflecting the strong effect of age on thyroid-cancer death.
• How likely is this to recur? → ATA initial risk (low/intermediate/high) — the more clinically actionable framework day to day, guiding radioiodine use and TSH suppression.

ATA Initial Risk (Recurrence)

Initial risk guides extent of radioiodine (often none/ablative in low risk; adjuvant/therapeutic in intermediate–high) and the initial TSH-suppression target.

Dynamic Response-to-Therapy Restratification

Initial risk is a starting estimate; response to initial therapy (surgery ± RAI) updates it using thyroglobulin (± antibodies) and imaging:

This makes risk a living variable — an initially intermediate-risk patient with an excellent response can be followed like a low-risk patient, and vice versa.

How It Drives Management

• Radioiodine decision: low-risk often needs no RAI or low-activity ablation; intermediate/high risk receives adjuvant/therapeutic activities (see the DTC and radioiodine pages).
• TSH suppression: intensity is graded to risk and response — deeper suppression for high-risk/structural-incomplete disease, relaxed toward normal for excellent responders (balancing recurrence risk against bone/cardiac harm of chronic suppression).
• Surveillance intensity: de-escalated for excellent response, intensified for incomplete responses.

Relationship to Imaging & Molecular Markers

Post-therapy whole-body scan findings feed ATA intermediate/high categorization; FDG-avidity and TERT/BRAF co-mutation mark biologically higher risk. RAI-refractory status (see the DTC page) is where dynamic restratification and imaging converge to redirect therapy away from more radioiodine.

Common Pitfalls

• Treating initial ATA risk as fixed — it must be updated by response to therapy.
• Confusing AJCC stage (mortality) with ATA risk (recurrence) — they answer different questions.
• Over-suppressing TSH in an excellent responder (unnecessary bone/cardiac risk).
• Interpreting Tg without antibody status (anti-Tg antibodies invalidate/mask Tg).

Board Pearls

Use two systems: AJCC/TNM (age-dependent, predicts mortality) and ATA initial risk (low/intermediate/high, predicts recurrence and drives the RAI + TSH-suppression decision). Then update with dynamic response-to-therapy restratification — excellent, indeterminate, biochemical-incomplete, or structural-incomplete.

An excellent response (undetectable Tg + negative imaging) lets you de-escalate surveillance and relax TSH suppression even in an initially higher-risk patient; a structural-incomplete response is the highest-risk state and prompts treatment.

AJCC staging's age threshold at 55 reflects age's strong effect on thyroid-cancer death, and is distinct from recurrence risk. Tg must be interpreted with anti-Tg antibodies, and RAI-refractory disease is where escalating radioiodine stops helping — dynamic restratification plus FDG-PET redirect care to systemic therapy/redifferentiation.

Related Pages

• Disease: Differentiated thyroid cancer (the three RAI intents, RAI-refractory disease).
• Tracer: Radioiodine (I-123 / I-131) — Thyroid.
• Nodule work-up: Thyroid nodule evaluation.

Figure / Diagram Suggestions

• A two-axis graphic: AJCC (mortality) vs ATA (recurrence).
• A dynamic restratification flow (initial risk → response category → updated management).
• A TSH-suppression intensity ladder by risk/response.

Self-Check (Board-Style)

Quick Answer

Medullary thyroid carcinoma (MTC) arises from parafollicular C cells, which do not express the sodium-iodide symporter — so radioiodine has no role (a common conceptual trap: the entire differentiated-thyroid-cancer RAI pathway is inapplicable). Management centers on complete surgical resection, with calcitonin and CEA kinetics (doubling times) driving surveillance and prognosis. For biochemical recurrence, functional imaging localizes disease — F-18-FDOPA is often the most sensitive, Ga-68-DOTATATE may guide PRRT, and FDG favors aggressive, short-doubling-time disease. RET testing is mandatory and enables selective RET-inhibitor therapy.

Background & Genetics

MTC secretes calcitonin (and CEA) from neuroendocrine C cells. It is sporadic (~75%) or hereditary (~25%) — MEN2A (with pheochromocytoma and primary hyperparathyroidism), MEN2B (with mucosal neuromas, marfanoid habitus, earlier/aggressive MTC), and familial MTC — all RET proto-oncogene-driven. Specific RET codons (e.g., M918T in MEN2B) predict aggressiveness and prophylactic-thyroidectomy timing.

Clinical & Laboratory

Thyroid nodule ± cervical nodes; diarrhea/flushing with high calcitonin. Calcitonin and CEA are the tumor markers; doubling times are the key prognostic/surveillance metric. In hereditary disease, screen for pheochromocytoma (plasma/urine metanephrines) BEFORE any neck surgery — an unrecognized pheo can precipitate intraoperative crisis.

Imaging by Scenario

• F-18-FDOPA PET/CT: often the most sensitive for localizing recurrent MTC, especially at moderate calcitonin levels.
• Ga-68-DOTATATE PET: variable SSTR expression; useful and may guide PRRT in selected SSTR-positive cases.
• FDG-PET/CT: favored in aggressive disease and short calcitonin/CEA doubling times (poor-prognosis marker).
• Neck ultrasound and CT/MRI for structural staging (liver MRI for hepatic metastases).

Interpretation & Decision

At biochemical recurrence, tracer choice tracks biology: FDOPA for general localization, DOTATATE to assess SSTR/PRRT candidacy, FDG when doubling times are short (aggressive). Multiple tracers are often complementary. RET status (germline for family screening; somatic for therapy) directs targeted treatment.

Differential Diagnosis

Differentiated (papillary/follicular) thyroid cancer (iodine-avid — the key contrast), C-cell hyperplasia, other neuroendocrine tumors, and anaplastic carcinoma. A non-iodine-avid thyroid malignancy should prompt consideration of MTC (calcitonin) or dedifferentiated DTC.

Reporting Checklist

• State that MTC is not iodine-avid (RAI inapplicable) when relevant.
• Report the tracer used and disease sites; correlate with calcitonin/CEA and doubling times.
• Note SSTR positivity (PRRT candidacy) on DOTATATE and FDG-avidity (aggressiveness).
• Recommend/confirm RET testing and, in hereditary disease, pheochromocytoma exclusion before surgery.

Common Pitfalls

• Attempting radioiodine work-up/therapy in MTC — no symporter, no mechanism.
• Relying on a single tracer; MTC imaging is often complementary (FDOPA + DOTATATE ± FDG).
• Operating before excluding pheochromocytoma in hereditary disease.
• Missing short doubling time as the flag for aggressive, FDG-avid disease.

Board Pearls

MTC arises from parafollicular C cells, which lack the sodium-iodide symporter — so radioiodine has no role (the entire DTC RAI pathway is inapplicable). Management is surgical, with calcitonin and CEA doubling times driving surveillance and prognosis. For recurrence, F-18-FDOPA is often the most sensitive localizer, Ga-68-DOTATATE may guide PRRT, and FDG favors aggressive, short-doubling-time disease. RET testing is mandatory and enables selective RET inhibitors (selpercatinib, pralsetinib).

Short calcitonin/CEA doubling time flags aggressive, often FDG-avid disease and poorer prognosis — pair FDG with the localizing tracers. SSTR expression is variable; DOTATATE positivity opens the PRRT option.

MTC is sporadic (~75%) or hereditary (MEN2A/2B, FMTC), all RET-driven — germline testing screens families and times prophylactic thyroidectomy. In hereditary disease, exclude pheochromocytoma before any neck operation (crisis risk). Imaging is frequently multi-tracer and complementary, matched to calcitonin level and doubling time.

Related Pages

• Tracers: DOTATATE, FDG; diseases: Neuroendocrine tumors, MEN syndromes.

Figure / Diagram Suggestions

• A tracer-by-biology decision aid (FDOPA localize / DOTATATE PRRT / FDG aggressive).
• A MEN2A vs MEN2B vs FMTC feature comparison.
• A doubling-time vs FDG-avidity prognostic schematic.

Self-Check

Quick Answer

Parathyroid imaging localizes a hyperfunctioning gland (usually a single adenoma) in primary hyperparathyroidism to enable minimally invasive, focused parathyroidectomy — it does not make the diagnosis, which is biochemical (hypercalcemia with inappropriately normal/high PTH). Tc-99m-sestamibi (dual-phase and/or SPECT/CT) is the traditional workhorse; ¹⁸F-fluorocholine PET/CT has higher sensitivity and is increasingly first-line, especially for small, sestamibi-negative, or multiglandular disease. 4D-CT and ultrasound are complementary; concordant localization on two modalities strongly supports a single-gland operation.

Background & Pathophysiology

Primary hyperparathyroidism is usually a single adenoma (~85%), less often four-gland hyperplasia or double adenomas, and rarely carcinoma. Excess PTH drives hypercalcemia, hypophosphatemia, bone resorption, and stones. Secondary/tertiary hyperparathyroidism (renal disease) involves multigland hyperplasia. Imaging matters only once surgery is planned — to convert a bilateral neck exploration into a targeted operation, often guided by intraoperative PTH monitoring (>50% drop confirms cure).

Clinical & Laboratory

Diagnosis is biochemical: hypercalcemia + inappropriately normal/high PTH (with low phosphate; elevated 24-h urine calcium excludes FHH). Symptoms — "stones, bones, groans, psychiatric moans" — or asymptomatic. Vitamin D repletion and FHH (low urine calcium, familial) must be considered before surgery.

Imaging Techniques

• Dual-phase sestamibi: adenomas retain sestamibi longer than normal thyroid (more mitochondria/oxyphil cells); early and delayed images show persistent focal uptake as thyroid activity washes out.
• Sestamibi SPECT/CT: adds anatomic localization — ectopic (mediastinal, retroesophageal, intrathymic) glands.
• ¹⁸F-fluorocholine PET/CT: higher sensitivity, particularly for small, sestamibi-negative, and multiglandular disease — increasingly preferred/first-line.
• 4D-CT / ultrasound: anatomic adjuncts; US operator-dependent; 4D-CT good for ectopic/re-operative cases.

Interpretation & Decision

Concordant localization (e.g., sestamibi + US, or fluorocholine + 4D-CT) strongly supports a focused, single-gland operation. A negative scan does not exclude disease — small or multiglandular adenomas are missed — and such patients may still proceed to bilateral exploration. Coexisting thyroid nodules are the classic sestamibi false positive (thyroid also concentrates the tracer).

Differential Diagnosis (of uptake)

Parathyroid adenoma vs thyroid nodule/adenoma (false positive), lymph node, thymus, and (for choline PET) other choline-avid tissue. Biochemical mimics: FHH, malignancy-associated hypercalcemia (PTHrP), vitamin D issues.

Reporting Checklist

• State the technique (dual-phase sestamibi ± SPECT/CT; fluorocholine PET/CT) and localization (side, level, ectopic sites).
• Report concordance across modalities.
• Explicitly note that imaging localizes, not diagnoses, and a negative scan does not exclude disease.
• Flag coexisting thyroid nodules as potential false positives.